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Interleukin 36α, -β and –γ (hence IL-36) are a group of innate cytokines that play a key role in epithelial 
immune homeostasis. In fact, mutations causing excessive IL-36 signalling have been associated with 
generalised pustular psoriasis (GPP), a severe autoinflammatory disease presenting with flares of skin 
pustulation and systemic upset.  
 
Given that GPP patients often suffer from concurrent plaque psoriasis (Ps), the hypothesis underlying 
this study was that abnormal IL-36 activity may also contribute to the pathogenesis of Ps. As the 
disease presents with cutaneous (red, scaly plaques) and systemic (increased cardiovascular risk) 
manifestations, the effects of IL-36 were examined in both contexts. 
 
In the first part of the research, a signature of IL-36 activation was defined through the transcription 
profiling of primary keratinocytes treated with IL-36α, -β or γ. This identified a core set of transcripts 
that are up-regulated by all three cytokines. Importantly, these differentially expressed genes (DEG) 
showed an enrichment for pathways related to IL-17 signalling and leukocyte chemotaxis, two 
processes that are critical to the pathogenesis of Ps. There was also a marked overlap between the 
genes that are up-regulated by IL-36 and those that are over-expressed in Ps skin.  
 
The second part of the study focused on the systemic effects of IL-36. These were initially investigated 
by whole-blood RNA-sequencing of GPP cases and unaffected controls. While the experiment 
confirmed the up-regulation of IL-36 dependent transcripts in GPP, it also showed an unexpected over-
expression of Type-I IFN stimulated genes. Signatures of abnormal IL-36 and Type-I IFN activity were 
also observed in Ps leukocytes. Follow-up experiments demonstrated that IL-36 acts directly on 





Taken together, these findings demonstrate that IL-36 plays an important role in the cutaneous and 





2.1 Autoimmunity and autoinflammation 
2.1.1 The immune system 
Antimicrobial responses appear very early in evolution. Even simple organisms like prokaryotes have 
a defence system against infectious agents. However, vertebrates have evolved a highly adaptable 
immune system that confers protection against pathogens through an array of specialised molecules 
and cells. These mediate two interconnected responses known as innate and adaptive immunity [1]. 
Innate immunity activates an early and non-specific response, which is mediated by evolutionary 
conserved receptors, encoded in the germline. Conversely, adaptive immunity drives a delayed and 
highly-specific response, whereby antigen presenting cells enable T and B lymphocytes to specifically 







Fig. 2.1.1. Innate and adaptive immunity.  
The figure (Dranoff et al. [2]) illustrates the different cell types mediating innate and adaptive 
immunity. While some cells can have a specialist function and only contribute to one type of 





2.1.1.1 Innate immunity 
The innate immune system ensures an early response against microorganisms. The first line of defence 
is provided by surface barriers (e.g. skin, lung and gut epithelia) affording mechanic, chemical and 
biological protection against pathogens [3]. Microbes that breach these barriers are recognised by 
pattern recognition receptors (PRR). These are encoded in the germline and can sense a variety of 
pathogen associated molecular patterns.  
PRRs include Nod-like receptors (NLRs), RIG-I like receptors (RLRs) and Toll-like receptors (TLRs). NLRS 
are a family of 22 cytosolic PRRs that detect PAMPs as well as endogenous molecules (e.g. ATP) and 
subsequently signal through NF-κB activation [4]. A number of NLRs such as NLR protein 3 (NLRP3) 
and NLR CARD Domain Containing 4 (NLRC4) are integral parts of the inflammasome, the multi-protein 
complex that processes the pro-inflammatory cytokines IL-1β and IL-18 into their active form [5]. 
Mutations of genes encoding subunits of this enzymatic platform lead to monogenic 
autoinflammatory diseases, as described later on in this chapter 
RLRs are a group of cytosolic receptors detecting viral RNA and inducing the production of type-I 
interferons. They specifically recognise features that are unique to viral genomes (e.g. double-
stranded RNA), thus avoiding the initiation of an inflammatory process by endogenous RNA [6]. 
Toll-like receptors (TLRs) are transmembrane proteins that recognize viral nucleic acids as well as 
bacterial components, including lipopolysaccharide (LPS) and lipoteichoic acids [7]. More specifically, 
cell-extrinsic recognition of viruses is mediated by TLR-3, TLR-7, TLR-8 and TLR-9, which are expressed 
in the endosomes (Fig. 2.1.1.1) [8]. Conversely, TLR-1, TLR-2, TLR-4, TLR-5, TLR-6 and TLR-11 reside 
on the cell surface and recognize a wide range of PAMPs, such as microbial membrane proteins and 
parasite components. Following ligand binding, TLR signalling is initiated by association with the 
Myd88 adaptor molecule. This is followed by a phosphorylation cascade resulting in the activation of 
the mitogen-activated protein kinase (MAPK) and NF-κB pathways and the transcription of cytokines, 




the IL-36 receptor. This suggests a potential convergence of the two signalling pathways, as explored 
in the result chapter.  
The key mediators of innate immunity are neutrophils, dendritic cells (DC), macrophages and natural 
killer (NK) cells [1]. These cells can sense pathogens through their PRRs and subsequently produce 
cytokines, chemokines and anti-microbial molecules. 
Neutrophils account for the majority of circulating white blood cells. Following chemokine-driven 
extra-vasation, they are the first cells to arrive at sites of inflammation, where they are activated by 
bacterial components such as LPS. Active neutrophils can then amplify the inflammatory response 
mediated by other cell types, and directly attack microorganisms by phagocytosis [1]. Importantly, the 
elimination of circulating microbes can also take place through the formation of neutrophil 
extracellular traps (NETs). NETs are web-like structures constituted of DNA, histones, proteins (e.g. 
cathepsins) and granule enzymes (e.g. neutrophil elastase). They have been shown to constrict 
pathogens and enable subsequent phagocytosis [9].  
Dendritic cells and macrophages are particularly important for relaying signals between innate and 
adaptive immunity. In fact, an important feature of these cells is the ability to phagocytise extracellular 
antigens and load them on class II major histocompatibility complex (MHC) molecules. The antigens 
are then presented to T helper (Th) lymphocytes, which become activated and initiate an adaptive 
immune response [1]. 
Finally, natural killer cells can recognise and kill virus-infected cells and also secrete essential 
inflammatory mediators such as Interferon-γ and TNF-α. 
Despite not being classified as immune cells, keratinocytes (KCs) play an important role in the response 
to pathogens that have breached the skin barrier. They express a vast array of PRRs, and therefore 
recognise numerous microbial components. This results in the secretion of defensins and cathelicidin, 




chemokines  (e.g. IL-8), cytokines (e.g. IL-1) and pro-inflammatory mediators such as CCL20 and 






Fig. 2.1.1.1 Toll-like receptors family  
The figure from Yamamoto et al. [11] illustrates the key features of Toll-like receptors (TLRs). These 
transmembrane proteins can be expressed on the plasma membrane (top panel) or in the endosomal 
(or lysosomal) membrane. TLRs are homo or heterodimers. Each subunit is composed by a cytosolic 







The term autoinflammation refers to an abnormal and seemingly unprovoked activation of the innate 
immune system, which occurs in the absence of autoantibody production or autoreactive T cells [12]. 
However, distinguishing between innate and adaptive causes of immune mediated diseases is not 
always trivial. There is evidence of autoimmunity in syndromes of a predominantly autoinflammatory 
nature, and innate immune system involvement in autoimmune disease [13]. Therefore, it has been 
proposed that immune-mediated disorders are distributed along a continuum between 







Fig. 2.1.1.2. The immune-mediated disease continuum, with examples. 
 
This representation, created by McGongal and McDermott [13], illustrates how monogenic 
autoinflammatory and autoimmune diseases represent the extremes of an immunological spectrum. 
Intermediate phenotypes may manifest with MHC involvement but still present with 





Inherited periodic fever syndromes sit at the autoinflammatory end of the spectrum. These Mendelian 
diseases are mostly caused by autosomal dominant mutations that lead to constitutive innate immune 
signalling. For example, TNF receptor-associated periodic syndrome (TRAPS), is caused by mutations 
of the tumour necrosis factor receptor (TNFR1) [12]. Disease alleles result in defective receptor 
clearance, leading to sustained TNF signalling and prolonged inflammation [14].  
Another key mechanism of autoinflammation is excessive ΙL-1β production. In fact, activating 
mutations in NLRP3, which is essential for IL-1 processing by the inflammasome, were found in 
individuals suffering from cryopyrin associated periodic syndromes (CAPS) [15]. These are a group of 
conditions of varying severity (familial cold autoinflammatory syndrome 1; Muckle-Wells syndrome 
and neonatal onset multisystem inflammatory disease), that typically present with recurrent fevers, 
urticarial skin rashes, neutrophilia and arthralgia or arthritis.  
The key role played by IL-1 in autoinflammation was confirmed by the discovery of truncating 
mutations of the interleukin 1 receptor antagonist (IL-1Ra) in individuals presenting with skin 
pustulation, recurrent fevers and osteomyelitis (Deficiency of Interleukin 1 Receptor Antagonist (DIRA) 
syndrome) [16]. Since genetic studies demonstrated the key role of IL-1 in the pathogenesis of CAPS 
and DIRA, significant progress has been made in the treatment of these conditions. In fact, the IL-1 
blocker anakinra ameliorates inflammation and its related symptoms in most disease cases [17]. 
Although the pathogenic potential of innate immune genes has been amply demonstrated, other 
mechanisms linking conserved cellular functions with autoinflammatory processes have recently 
emerged [18]. For instance, mutations in genes required for immunoproteasome function (e.g. 
PSMB8, PSMB9 and PSMG2) cause abnormal type I IFN production and sustained inflammation [19]–
[21]. As other disease alleles de-regulating type I IFN responses have been identified in STING, IFIH1 
and DDX58, the term “Interferonopathies” was coined to describe monogenic autoinflammatory 




of IFN signalling in these conditions, patients treated with JAK1/2 inhibitors showing beneficial 
improvements [23].  
2.1.1.3 Adaptive immunity 
While the innate immune system provides rapid sensing and elimination of pathogens, slower 
adaptive responses have higher specificity and long-lasting effects (immune memory). 
Cells of the adaptive immune system include the T lymphocytes, which mature in the thymus, and the 
B lymphocytes, which arise in the bone marrow. These cells then traffic to secondary lymphoid organs, 
including lymph nodes and the spleen, which capture circulating antigens from the lymph and blood, 
respectively [24].  
Naive T cells are activated upon interaction of their T cell receptor (TCR) with antigenic peptides 
complexed with major histocompatibility complex (MHC) molecules. Peptides produced from proteins 
translated within the cell are typically MHC class I–restricted (i.e. presented only by human leukocyte 
antigen (HLA)-A, HLA-B and HLA-C). Conversely, extracellular antigens are generally MHC class II 
restricted (presented by HLA-DR, HLA-DQ, and HLA-DP) [25]. Unlike MHC class I proteins, which are 
constitutively expressed in all nucleated cells, MHC class II molecules are only present on antigen 
presenting cells (APCs) and are inducible by innate immune stimuli, including TLR ligands.  
APCs can be found in the skin and mucosal sites, where pathogen encounter is most likely. Of note, 
keratinocytes can act as APCs by presenting lipid generated by phospholipase A2 to CD1a-reactive T 
cells. However, this mechanisms is mediated by resident Langerhans cells [26], [27]. Other APCs, 
instead, migrate to regional lymph nodes, where the interaction with T cells occurs, leading to 
initiation of immune responses [24], [25].  
T cells can be classified into different classes (Fig. 2.1.1.3). The largest group are CD4+ T cells, which 
have a helper function and are consequentially designated as Th cells. Two main categories of T helper 




IL-12 and IFN-γ, are characterized by the production of IFN-γ and IL-2. In contrast, Th2 cells require IL-
4 for their development and produce IL-4, IL-5, IL-10, and IL-13.  
However, not all CD4+-driven processes could be attributed to cytokines predicted to arise from Th1 
or Th2 responses [29]. The discovery of a third Th subset filled this research gap. Th17 cells are induced 
by IL-6 and TGF-β. They mainly produce IL-17A, IL-17F, IL-21 and IL-22. These are potent 
proinflammatory cytokines capable of inducing IL-6 and TNF production, as well as driving granulocyte 
recruitment to damaged tissues [30].  
The existence of IL-9–producing Th9 cells has recently been suggested by the observation that 
exposure of Th2 cells to a combination of IL-4 and TGF-β reprograms them to produce IL-9, a potent 
mast cell growth factor and mediator of anti-parasite immunity [31], [32].  
The regulation of T-cell responses also resides within the CD4+ subset of lymphocytes which, in 
response to TGF-β and IL-2, acquire the expression of FOXP3, leading to the activation of a new 
transcriptional repertoire. The change in gene expression allows this specialised cell-type, called T 
regulatory (T regs) cells, to suppress immune responses, thereby maintaining homeostasis and self-
tolerance [33].  
The second largest group of T cells, CD8+ T cells, acts to remove viruses and transformed cells. CD8+ 
T cells are primarily activated by antigenic peptides presented on MHC class I molecules. Recognition 
of these cytosolic peptides then leads to apoptotic death of the target cell. This process is mediated 
by rapid mobilization of CD8+ T cell granules and exocytosis of their contents, including granzymes 
and perforin [34].  
Natural killer T (NKT) cells represent another T cell subset, which recognize non-peptide antigens 
presented by non-classical MHC molecules of the CD1 family. Activated NKT cells are capable of rapid 
and substantial production of cytokines, including IL-4, and have been implicated in allergic 





Fig. 2.1.1.3. T cells phenotypes. 
 
The diagram (adapted from www.step1.medbullets.com) shows the development of T cells from the 
bone marrow, where they originate, to the thymus, where they differentiate into CD4+ or CD8+ 
subsets. The latter migrate to secondary lymphoid organs where they become polarises towards 





Adaptive humoral immunity is mediated by antibodies produced by fully differentiated B cells (also 
known as plasma cells). These arise from haemopoietic stem cells in the bone marrow, where 
commitment to the B-cell lineage is under the control of several transcription factors, such as PU.1, 
IKAROS (IKAROS family zinc finger 1), E2A, EBF (early B cell factor 1), PAX5 (paired box gene 5) and 
IRF8 (interferon regulatory factor 8) [36], [37]. Once they have acquired antigen specificity and left the 
bone marrow, immature B cells complete their development to the mature naive stage. This requires 
the expression of IgD, as well as IgM, on the cell surface. The entire process occurs in the absence of 
any contact with exogenous antigens. Thus it is known as antigen-independent B-cell development.  
The second phase of B-cell development occurs after the encounter with an antigen and is therefore 
called the antigen-dependent activation phase. This requires two signals. The first one is 
immunoglobulin receptor cross-linking. The second is the interaction between B and T cells. When the 
B cell contacts a CD4+ T cell that is specific for the peptide presented on the B cell-MHC class II 
molecule, the T cell is able to activate the B cell for further differentiation. Depending on the various 
contacts and cytokine stimuli received by the activated B cell, it will become either a memory cell or a 







Fig. 2.1.1.3.1. B cell development. 
 
This figure from Cambier et al. [38] illustrates how B-cell development occurs in the bone marrow and 
in peripheral lymphoid tissues such as the spleen. In the bone marrow, development progresses up to 
the immature B cell stage via sequential immunoglobulin re-arrangements. B cells then undergo a 
selection process to prevent any further development of self-reactive cells. Cells that have passed this 
checkpoint leave the bone marrow as transitional B cells, eventually maturing into memory B cells or 







Autoimmunity is a response of the immune system against self-antigens. Under normal circumstances, 
adaptive immune cells and APCs undergo a process of “education” in the germinal centre, so they can 
discriminate between host (self) and microbial (non-self) proteins. When the tolerance to self is 
broken, the organism starts to produce auto-antibodies and auto-reactive T cells, which lead to the 
development of autoimmune diseases. 
The causes of autoimmunity are thought to be an interplay between genetic and environmental 
factors. In this context, genome-wide association studies (GWAS) have identified very significant HLA 
associations (e.g. HLA-DQA1*0501 in celiac disease or HLA-DRB1*1501 in multiple sclerosis) [39]. 
While these tend to be disease specific, several susceptibility genes that contribute to multiple 
autoimmune diseases have also been identified [40]–[42]. These include various genes that mediate 
the effects of IL-23 on the polarization of Th17 cells [43]. For example genetic polymorphisms in IL23R 
(which encodes a subunit of the IL-23 receptor) have been associated with ankylosing spondylitis, 
Behcet’s disease, Crohn’s disease, psoriasis, and ulcerative colitis [44]. Of note, targeting the IL-
23/Th17 axis with monoclonal antibodies specific for either p40 (a subunit of IL-23) or IL-17A has 
shown efficacy in many of these disorders [45], [46].  
While autoimmune diseases are often described as complex polygenic disorders, disruption of a single 
gene can in some cases result in breach of self-tolerance. Perhaps the two best known examples of 
this phenomenon are autoimmune polyendocrine syndrome (APS) and immunodysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome. These diseases result from mutations in 
AIRE and FOXP3, respectively, leading to catastrophic dysfunction in central (APS) and peripheral 





2.2 IL-36 cytokines 
2.2.1 Overview 
The term interleukin (IL)-36 refers to a group of IL-1 family cytokines that bind a common 
heterodimeric receptor (IL-36R). These ligands include three pro-inflammatory proteins (IL-36α/IL-
1F6, IL-36β/IL-1F8 and IL-36γ/IL-1F9) and a receptor antagonist (IL-36Ra/IL-1F5). 
The IL-36 receptor is composed of a signalling subunit (also known as IL-1Rrp2 and encoded by the 
IL1RL2 gene) and an accessory protein (IL-1RAcP, encoded by IL1RAP). While IL-1Rrp2 only binds IL-36 
cytokines, IL-1RAcP is also a component of the IL-18 and IL-33 receptors [49]. 
2.2.2 Expression and processing of IL-36 
The genes encoding IL‐36 cytokines are clustered on human chromosome 2q14 together with those 
for all other IL‐1 family cytokines (except for IL18 and IL33, which map to chromosome 11p14 and 
9p24, respectively) [50]. 
Like all other IL‐1 family members (except for IL‐1Ra), IL-36 cytokines are produced as inactive 
precursors that require proteolytic processing for activation (Fig. 2.2.1). In fact, Towne and colleagues 
have found that removal of a small number of residues from the N‐termini of IL‐36α, IL‐36β and IL‐36γ 
(IL-36) increases their biological activity by greater than 10 000‐fold [51]. Clancy et al. have built on 
these data to show that IL-36 can be processed by caspase-3 with high specificity. Others have 
demonstrated that cathepsin S, which is up-regulated in skin inflammation, can also cleave IL-36 [52]. 
Finally, elastase, a protein produced by neutrophils during inflammation, has been identified as a 
proteinase that specifically activates IL-36γ and IL-36Ra [53], [54]. 
The IL-36 cytokines are expressed in a variety of cell types, with abundant transcript levels observed 
in keratinocytes, bronchial epithelium, gut mucosa, neurons, glial cells, dendritic cells (DCs) and 
macrophages. In most of these cell types, IL‐36 levels are further increased in response to 




[55]) and cigarette smoke [56], [57]. IL1RL2, on the other hand, is widely expressed. Transcript levels 







Fig. 2.2.1. Overview of IL-36 signalling. 
Interleukin (IL)-36 is originally synthesised as an inactive precursor (pro-IL36) that requires N-terminal 
processing. Once IL-36 has bound its receptor (IL-1Rrp2), a heterodimeric complex is formed which is 
capable of signalling. IL-36Ra antagonizes this process by binding to IL-36R in a fashion that blocks the 





2.2.3 IL-36R signal transduction 
IL-36R signalling shares common features with IL-1R signal transduction. Both receptors are 
heterodimers and share the same accessory protein (IL-1RAcP). The latter is composed of an 
extracellular ligand-binding domain, a single-pass transmembrane sequence, and a cytoplasmic Toll-
IL-1 receptor (TIR) domain. The binding of the agonists stabilises the accessory protein, which induces 
conformational changes in the TIR domain. The protein complex then recruits the adaptor protein 
MyD88, IL-1 receptor-associated kinase 1 (IRAK-1), and the Toll-interacting protein (Tollip), leading to 
the activation of transcription factors such as NF-κβ and IBz. (Fig. 2.2.2). This in turn leads to the 
expression of innate immune cytokines (e.g. IL-6 and IL-8) [59], chemokines (CCL3, CCL4, CCL20) [61], 
anti-microbial peptides (e.g. LL37) and matrix metalloproteinases [62]. While other pro-inflammatory 
mediators are likely to be up-regulated by IL-36, most studies investigating its effects were based on 
the use of unprocessed molecules with minimal biological activity. Thus, our understanding of IL-36 







Fig. 2.2.2. IL-36R activation and downstream signalling cascade. 
Once IL-36 precursors have been processed, they bind to IL-36R, which associates with IL-1RAcP. The 
first downstream event is then activation of the TIR, which in turn triggers NF-ⱪB and MAPK signal 





Despite other similarities with IL-1R, IL-36R intracellular trafficking follows a distinct pattern. In-vitro 
experiments by Saha and colleagues showed that in the absence of an antagonist, IL-36R cycles into 
endosomes and back to the plasma membrane. Exposure of HaCat cells to IL-36 alters the dynamics 
of this process, so that an increased proportion of the IL-36R enters the lysosomes where it is 
degraded. IL-36 also increases the co-localization of Tollip and IL-36R in the endosome. These results 
suggest that Tollip is involved in IL-36R trafficking and that the presence of agonists acts as a feedback 





2.2.4 The immune function of IL-36 
2.2.4.1 IL-36 and response to pathogens 
Like other cytokines of the IL-1 family, IL-36 contributes to the response against pathogens that invade 
barrier tissues, such as skin, gut and lungs.  
The role of IL-36 in the defence against Aspergillus fumigatus and Candida albicans is well established 
[55], [64]. In fact, PBMCs exposed to A.fumigatus produce IL-36γ in a TLR-4 dependent fashion [55]. 
Moreover, IL-36Ra treatment reduced A.fumigatus (or C.albicans) dependent Th17 polarization and 
consequent IL-17 production [64], [65].  
Accumulating evidence also supports a role of IL-36 in immunity in tuberculosis. IL-36R knockout mice, 
for example, produce less Th1 cytokines (IFNγ, TNFα and IL-6) than wild type littermates, when 
infected with Mycobacterium bovis Bacillus Calmette-Guérin (BCG) [66]. The pulmonary lesions of IL-
36R deficient mice were also more extensive than those of wild type animals, indicating that IL-36 
mediated immune responses protect from damage induced by infection. Additionally, recent in-vitro 
studies demonstrated that Mycobacterium tuberculosis can induce IL-36γ production in human 





2.2.4.2 Effects of IL-36 on immune cells 
Despite the distinction between adaptive and innate immunity, their interplay is essential for an 
efficient response to infections. In this context, accumulating evidence suggests that IL-36 has a key 
role in the cross-talk between antigen presenting cells and T lymphocytes, leading to the polarization 
and activation of the latter cell type.  
Vigne et al. first showed that in murine myeloid dendritic cells (mDCs), IL-36 upregulates activation 
markers such as CD80, CD86 and MHC class II molecules. It also induces IL-6 and IL-12 production [68]. 
Moreover, stimulation of murine CD11+ cells with IL-36α upregulates CXCL1 and CXCL2, which are 
potent neutrophil chemoattractant [69].  
In humans, abundant IL-36R expression has been reported in myeloid DCs, including monocyte-
derived DCs (MDDCs). The latter respond to IL-36β and IL-36γ by up-regulating activation markers 
(HLA-DR and CD83) and cytokine (IL-12 and IL-18) release [70].  
Vigne et al also showed that IL-36 is highly expressed in naïve CD4+ T cells and synergizes with IL-2 in 
driving Th1 polarization [65]. Furthermore, Harusato et al. reported that IL-36 activates MyD88-NF-ⱪB 
in CD4+ T cells to potently inhibit the development of Foxp3-expressing regulatory T cells (Treg) [71]. 
Concomitantly, IL-36 can also influence Th9 polarization through IL-2-STAT5- and IL-4-STAT6-
dependent pathways. Thus, IL-36 seems to play a key role in Th9-Treg balance that, if disrupted, can 
lead to intestinal inflammation and associated chronic disorders [71].  
It is important to bear in mind, however, that most of these studies were carried out in mice, so that 
the results may not apply to human T cells. It is also unclear whether the above observations reflect a 
direct effect of IL-36 on T cells, given that the receptor is not detectable on the surface of human, 




2.2.4.3 Pathogenic effects of IL-36 
While IL-36 plays an important physiological role in anti-fungal and anti-mycobacterial defences, 
accumulating evidence indicates that it can also have pathogenic effects, if produced in excessive 
amounts (Fig.2.2.3). 
Since the expression of IL-36 cytokines is especially prominent in keratinocytes, it is not surprising that 
most studies have focused on skin disorders. In particular, IL-36 has been repeatedly investigated in 
the context of psoriasis.  
Several reports show that psoriatic skin lesions over-express IL-36R ligands [62], [72]–[74]. This is 
supported by the observation of skin acanthosis and hyperkeratosis (which are key characteristics of 
psoriatic lesions) in transgenic mice over-expressing IL-36α [38]. Importantly, IL-36Ra deficiency 
exacerbates the phenotype of IL-36α transgenic mice, suggesting that IL-36Ra antagonises IL-36 
mediated skin inflammation in-vivo [72].  
There have also been reports of an association between psoriatic arthritis and SNPs mapping to the 
IL36B/IL36RN gene region [75]. Moreover, our group and others have demonstrated that mutations 
in IL36RN cause generalised pustular psoriasis (GPP), a rare and potentially life-threatening disease 
manifesting with flares of neutrophilic skin inflammation [76]–[80] (see section 5.7).  
IL-36 has also pro-inflammatory effects beyond skin. IL-36α, for instance, is expressed by adipocytes 
and M2 macrophages present in adipose tissue during inflammation [81].  
In the airways, IL-36α administration up-regulates the murine CXCL1 and CXCL2 chemokines, 
promoting an influx of neutrophils in the lungs. A similar phenomenon is observed in the nasal 
epithelial cells of patients with chronic rhinosinusitis, where abundant IL-36γ expression leads to 




In inflamed synovial tissue, especially in patients with psoriatic or rheumatoid arthritis, infiltrated 
CD138+ plasma cells actively produce IL-36α. In keeping with these findings, serum IL-36 levels 
correlate with disease activity [82], [83]. 
In dextran-sulphate sodium (DSS) induced ulcerative colitis, IL-36 plays a critical role in driving the 
recruitment of immune cells (especially macrophages and neutrophils) to the lamina propria [84]. In 
fact, Il1rl2 knockout mice suffer from less severe chronic colitis and intestinal fibrosis, following DSS 
administration [85]. In keeping with these findings, the expression of IL-36 is elevated in the colonic 
mucosa of ulcerative colitis patients [84]. 
Finally, local IL-36α over-expression in the kidney is associated with tubule-interstitial lesions in mouse 
models of chronic glomerulonephritis, systemic lupus erythematosus (SLE), nephrotic syndrome and 






Fig. 2.2.3. Effect of IL-36 on different tissues and tissue-specific disorders. 
IL-36 cytokines are key mediators of inflammation in several tissues. The diagram shows the IL-36 
cytokines that have been implicated in the pathogenesis of organ-specific inflammatory diseases. 






Psoriasis is a chronic, immune-mediated skin disorder with a prevalence of 2-3% in populations of 
European descent. Males and females are equally affected and the disease is often associated with 
comorbidities, such as psoriatic arthritis [87]–[89].  
Psoriasis can be classified in different forms, based on the nature and localization of skin lesions (Table 
2.3, Fig. 2.3.1). Given that the focus of this thesis is on plaque and generalised pustular psoriasis, these 





Table.2.3. Classification of psoriasis clinical variants 
Type of psoriasis Most affected areas Characteristic lesions 
Plaque  Scalp, elbows, trunk Plaques covered with white scales 
Pustular  Widespread lesions (generalised 
pustular psoriasis); palms and soles 
(palmar plantar pustlosis) 
Sterile pustules  
Guttate Trunk and limbs Plaques with a fine adherent scale 
Erythrodermic > 90% of total body surface Generalised erythema and scaling 
Inverse Skin folds Plaques with minimal scale 







Fig. 2.3.1. Classification of psoriasis. 
Examples of the different forms of psoriasis described in Table 2.3. From the top-left: plaque, guttate, 
pustular and erythrodermic psoriasis. Images from Hon Pak, M.D. published on eMedicine.net. 




2.3.1 Plaque Psoriasis 
2.3.1.1 Clinical presentation 
Plaque psoriasis (Ps, also known as Psoriasis Vulgaris (PsV)) is the most common form of psoriasis, 
accounting for >90% of disease cases [90]. 
It classically presents with well demarcated, erythematous plaques with loosely adherent silvery 
scales. These lesions have a symmetrical distribution and most commonly affect the scalp or extensor 
surfaces, such as elbows and knees.  
The physical burden of the disease is increased by co-morbid conditions, such as seronegative psoriatic 
arthritis, which affects up to 30% of patients [8]. Several observational studies have also identified an 
elevated cardiovascular risk among patients with severe psoriasis [9]–[11].  
At the histological level [12], psoriatic plaques are characterised by the presence of hyperproliferative 
keratinocytes that retain their nuclei, even in the uppermost layers of the epidermis (parakeratosis). 
This is due to incomplete terminal differentiation, as demonstrated by reduced expression of keratin 
10.  
T lymphocytes and dendritic cells (DC) densely infiltrate psoriatic lesions. Neutrophils also accumulate 
in 'Kogoj pustules' and 'Munro's microabscesses', which appear in the stratum spinosum and stratum 
corneum of the epidermis, respectively. Finally, the erythematous appearance of lesions is due to 






Epidemiological surveys have long demonstrated that Ps is more frequent among the relatives of 
affected individuals compared to the general population [91]. Moreover, a higher disease 
concordance has been consistently observed in monozygotic compared to dizygotic twins, with 
heritability estimates ranging from 60 to 90% [92]. As a result, Ps is widely considered as a 
multifactorial trait, mediated by an interplay between inherited susceptibility alleles and 
environmental factors.  
Linkage studies carried out in the 1990s identified various loci co-segregating with the disease in 
multiplex pedigrees. The most reproducible signal was observed in the so-called PSORS1 region, which 
maps to the class I interval of the major histocompatibility complex (MHC) and explains 35-50% of 
disease heritability [93]–[95]. The linkage signal is driven by the HLA- Cw*0602 allele, which has been 
repeatedly described as the strongest genetic determinant of the disease [96]–[98].  
Disease associated variants have also been identified within the PSORS2 locus on chromosome 17q25 
and, more specifically, in the CARD14 gene, which encodes a nuclear factor-κB (NF-κB) activator. 
Jordan et al first reported deleterious CARD14 mutations in extended pedigrees presenting with rare 
monogenic forms of Ps [99]. Further studies then showed that common CARD14 alleles are also 
associated with the disease in the general population [100].  
With the advent of genome wide association studies (GWAS) >40 additional psoriasis susceptibility 
loci have been identified. These include genes involved in antigen presentation (ERAP1), Th17 cell 
activation (e.g. IL23R, IL23A, IL12B, TRAF3IP2) and skin barrier function (LCE3B/3D) [101]–[104]. The 
analysis of targeted genotyping arrays, such as the Immunochip and exome chip, uncovered further 
susceptibility loci and further confirmed the role of the IL-23/Th17 axis in disease pathogenesis [100], 
[105], [106].  
Despite these achievements, only 5% of lead SNPs described to date are likely to be causal [107] and 




need for further genetic studies, including the fine mapping of susceptibility intervals and the analysis 
of non-European datasets [111].  
2.3.1.3 Immunopathogenesis 
Psoriasis can be initiated by trauma, virus infections and certain drugs (such as recombinant IFN-α) 
[112]. Interestingly, all these triggers cause keratinocytes to secrete cathelicidin/LL37. This is a small 
antimicrobial peptide that can bind self-RNA or self-DNA released by dying cells. The resulting 
complexes breach tolerance to self-nucleic acids and activate plasmacytoid dendritic cells (pDC) via 
Toll-like receptor (TLR)-9 [113]. Myeloid dendritic cells (mDC) are subsequently activated by pDC-
derived type I interferon or through a direct interaction between TLR-8 and LL37/RNA complexes 
[114]. 
mDCs then migrate to sites of inflammation where they induce Th17 polarization and IL-17 production 
[115].  
In skin, IL-17 acts mainly on keratinocytes, where it induces the transcription of chemokines  that 
attract further DCs and Th17 cells (e.g. CCL20), as well as neutrophils (IL-8) [116], [117]. Thus, IL-17 
molecules produced by Th17 cells activate a positive feedback loop, leading to sustained cytokine 
secretion and chronic inflammation (Fig. 2.3.2). 
Given the critical role of T cell activation in disease pathogenesis, the existence of Ps auto-antigens 
presented by mDCs has been hypothesized. In fact, recent research has demonstrated that peptides 
derived from LL37 may be recognised by T cells in a HLA-Cw*0602 restricted manner [118]–[120]. 
Other studies have highlighted a potential role of lipid antigens generated by phospholipase A2 and 







Fig. 2.3.2. Current understanding of plaque psoriasis pathogenesis  
 
The diagram from Greb et al.[122] illustrates the complex pathogenic cross-talk between immune cells 
and keratinocytes. Following trauma or infection, activated keratinocytes produce LL37 (CAMP), which 
up-regulates type-I IFN production in pDCs. The resulting inflammatory response is amplified by mDCs 
through the secretion of IL-23 and subsequent polarization of Th17 cells. These release IL-17 which 






The therapeutic approaches used to treat psoriatic patients vary, based on the severity of the disease 
and the presence of comorbidities. Topical agents remain the first-line therapy for patients with mild-
to-moderate psoriasis. They can be used as standalone treatment or in combination with 
phototherapy, which suppresses Th17 differentiation and promotes activation of regulatory T cells 
[123], [124].  
For individuals affected by severe disease the use of biologics (monoclonal antibodies that target 
specific inflammatory cytokines) is recommended, as these agents have shown great therapeutic 
efficacy. 
TNF-α antagonists (adalimumab, etanercept and infliximab) were the first biologics used for the 
treatment of Ps. They suppress Th17 differentiation by inhibiting IL-23 production by mDCs [125], 
[126]. Ustekinumab has also been used in the clinic for several years. It is an inhibitor of the common 
subunit shared by IL-12 and IL-23 (p40) and antagonises both Th1 and Th17 function [46], [127], [128]. 
More recently, the results of GWAS have informed the development of new agents that selectively 
target IL-17. These include secukinumab and ixekizumab, two IL-17A monoclonal antibodies, which 
have shown superior efficacy to ustekinumab [129]–[131]. While the efficacy of IL-17 antagonists 
supports the role of IL-17 as a key disease driver, this cytokine is also important for anti-microbial 
immunity. In fact, increased rates of Candida infections have been reported after pharmacological IL-
17 blockade [130], [131]. 
Following the success of ustekinumab, selective IL-23 blockers are also being developed. Two agents 
(Risankizumab and Guselkumab) have already been approved, as they have demonstrated rapid and 





Finally, Janus kinase (JAK) inhibitors are a new class of small molecule inhibitors, which act on the 
tyrosine kinases that activate STAT proteins (Fig. 2.3.3). Tofacitinib (a JAK-1/-3 inhibitor) demonstrated 
non-inferiority to etanercept in a phase III clinical trial, with sustained efficacy over 1 year [133], [134]. 
Encouraging results were also obtained in a phase II clinical trial of a TYK2 inhibitor [134]. Interestingly, 
the study’s participants were not responding to other treatments, so that selective TYK2 inhibition 
could offer an alternative for the treatment of mild to severe psoriasis.  
In conclusion, advances in characterising molecular disease mechanisms have successfully translated 
into the development of targeted immunotherapies for plaque psoriasis. However, the current 
pathogenic models are not sufficiently sophisticated to account for the heterogeneity of the disease 







Fig. 2.3.3. Psoriasis targeted immunotherapy. 
 
The diagram from Mahil et al [135], illustrates the molecules that can be targeted in order to treat 
plaque psoriasis. The most effective drugs target the IL-23/Th17 axis. They inhibit IL-23 signalling by 
competing with the binding of the cytokine to its receptor (Ustekinumab, Tildrakisumab and 
Guselkumab) or by blocking signal transduction downstream of IL-23R activation (JAK inhibitors). 
Several drugs have also been developed to inhibit Th17 activity by targeting IL-17 binding to its 
receptor (Ixekizumab and Secukinumab) or blocking IL-17R itself (Brodalumab). The genes highlighted 
in yellow have all been identified as psoriasis susceptibility loci in GWAS, demonstrating the power of 





2.3.2 Generalised Pustular Psoriasis 
2.3.2.1 Clinical presentation 
The term pustular psoriasis refers to a group of inflammatory disorders presenting with the eruption 
of sterile pustules on erythematous skin. These are painful lesions, that are histologically characterised 
by diffuse infiltration of neutrophils in the dermis and the epidermis [136], [137] (Fig. 2.3.2.1). 
While pustular forms of psoriasis often have a chronic localised course (palmar plantar pustulosis, 
acrodermatitis continua of Hallopeau), an acute generalised form is also well recognised.  
Generalised pustular psoriasis (GPP) is a very rare (prevalence 1-9:1,000,000), but potentially life-
threatening condition. It is characterised by acute episodes of pustulation and widespread erythema, 
which are often complicated by systemic upset (high fever, increased levels of acute phase reactants, 
neutrophilia).  
According to the consensus diagnostic criteria agreed by the European Rare and Severe Psoriasis 
Expert Network (ERASPEN), the pustules have to be sterile and macroscopically visible [138]. In fact, 
very small pustules can appear on the edges of plaques, in patients suffering from severe and unstable 
Ps. This phenotype, however, does not meet the criteria for a GPP diagnosis and is considered a 
manifestation of plaque psoriasis [139]. 
Another condition confounding the diagnosis of GPP is acute generalised exanthematous pustulosis 
(AGEP). This is an adverse reaction to certain drugs (antibiotics, anticonvulsants, antihypertensive, 
antipyretics, chemotherapeutics, antifungal and antimalarial agents), manifesting with the abrupt 
onset of pustular eruptions. AGEP episodes, however, tend to be shorter than GPP flares and are 
usually self-limiting. Given that AGEP does not recur in the absence of the culprit drug, a history of 
repeated pustular eruptions is usually sufficient to discriminate between GPP and AGEP [140], [141].  
GPP flares can be triggered by pregnancy, infection and certain drugs [142]. The mean age of onset is 




patients present with concomitant plaque psoriasis [144], suggesting the existence of shared 






Fig. 2.3.2.1. Histology of pustular psoriasis. 
Histology of inflamed skin showing neutrophilic pustules and acanthosis. Haematoxylin-eosin stain; 






Pustular psoriasis has a distinct genetic architecture to plaque psoriasis, which is underscored by a 
lack of association with the PSORS1 locus [146]. Indeed, the severity and rarity of the clinical 
phenotype suggested the involvement of rare and deleterious disease alleles, rather than common 
variants of small effect.  
This model was validated by the discovery of recessive GPP mutations in the gene encoding the IL-36 
receptor antagonist (IL36RN) [77]. Given the phenotypic similarities with the deficiency of the 
interleukin-1 receptor antagonist (DIRA, an autoinflammatory condition presenting with early onset 
generalized pustulosis, multifocal osteomyelitis, and high levels of acute-phase reactants [147]), the 
acronym DITRA (deficiency of interleukin thirty-six-receptor antagonist) has been subsequently 
proposed to describe generalised pustular psoriasis resulting from IL36RN mutations [76].  
Follow-up studies have demonstrated that IL36RN disease alleles are the strongest genetic 
determinant of GPP in all examined ethnic groups. In populations of European descent, p.Ser113Leu 
is the by far the most frequent change, whereas c.115+6T>C and p.Pro27Leu founder alleles dominate 
in Asian and North-African cohorts, respectively [76], [77], [148].  
On the whole, IL36RN mutations are found in ~25% of GPP cases. While these disease alleles were 
originally described as recessive, individuals harbouring a single heterozygous change have also been 
observed [143]. Interestingly, the onset of the disease is delayed in patients who carry monoallelic 
IL36RN changes [143]. 
When IL36RN is mutated, sustained IL-36 signalling leads to enhanced NF-κB and MAPK activation, 
with abnormal production of innate pro-inflammatory cytokines (Fig. 2.3.2.2). In fact, ex-vivo IL-36 
stimulation of patient PBMCs (peripheral-blood mononuclear cells) leads to excessive release of IL-1α, 
ΙL-6, IL-8 and TNF[77]. Likewise, patient-derived keratinocytes produce high levels of IL-8 after IL-36, 




Importantly, IL36RN mutations do not contribute to Ps susceptibility, as screening of 349 unrelated 
cases did not identify any enrichment for damaging changes in the IL-36 receptor antagonist [149]. 
Likewise, genome-wide association studies did not detect any Ps associated alleles within the IL36RN 
gene region [65]. 
While IL-36 is up-regulated in Ps skin, these observations suggest that abnormal IL-36 signalling is not 
a primary disease driver in this condition. 
Following the identification of IL36RN mutations, disease associated alleles were also detected in 
other genes. For example, mutations in CARD14, a gene encoding a skin-specific NF-κB activator, has 
been linked to disease pathogenesis [99], [150], [151]. Despite CARD14 mutations account for a 
minority of psoriatic patients, they have been found in both Ps and, more significantly, in GPP patients 
[152]. 
Whole-exome sequencing of GPP patients also revealed disease associated alleles in AP1S3. This 
encodes a protein involved in autophagosome formation which, if disrupted, leads to abnormal 
accumulation of p62 (an NF-kB adaptor) and up-regulation of IL-36 in keratinocytes [153]. This is an 







Fig. 2.3.2.2. IL-36 signal transduction. 
IL-36 cytokines, similar to other IL-1 family members, can activate the MAPK and NF-κB pathways by 
binding to the corresponding receptor, IL-1RAcP. When IL36RN is mutated, the IL-36R antagonist 
cannot inhibit the binding of the other ligands leading to sustained activation of signal transduction. 






While the immune pathogenesis of GPP was until recently very poorly understood, genetic and 
transcriptomic studies carried in the last few years have shed some light on disease pathways. 
As the rarity of GPP has hindered the recruitment of sizeable patient cohorts, only one transcription 
profiling study has been undertaken in patient skin [155]. This confirmed the up-regulation of IL-1 and 
IL-36 cytokines, as well as the over-expression of neutrophil-derived proteases (e.g. elastase and 
cathepsin G), which can process IL-36 precursors into mature cytokines [156]. These changes were 
observed regardless of the presence of IL36RN mutations, confirming the notion that IL-36 plays a 
fundamental role in the pathogenesis of GPP.  
IL-36 can up-regulate innate cytokines such as IL-1 and IL-8. While the former contributes to the acute 
phase response, IL-8 acts as a neutrophil chemoattractant [61], [157]. Of note, IL-36 also has an effect 
on endothelial cells, where it induces the expression of adhesion molecules (e.g. ICAM-1), thus 
facilitating the extravasation of neutrophils into inflamed skin [158]. 
Thus, genetic and immunological studies support the notion that GPP is an autoinflammatory 
condition, driven by excessive IL-36 signalling and abnormal neutrophil activation. 
Despite these advances, the molecular pathways underlying the concurrence of Ps (a T-cell mediated 
disorder) remain ill-defined. Moreover, little is known about the role of IL-36 in the systemic 






First line therapies for GPP include acitretin, methotrexate, cyclosporine and infliximab. While these 
agents are often used with good effect for the treatment of plaque psoriasis, they are often ineffective 
in the pustular forms of the disease [137].  
Given the role of  IL-1 in other autoinflammatory diseases, IL-1 receptor blockers have been used in a 
small number of cases, leading to rapid clinical improvements but not full disease remission [159], 
[160]. This supports the notion that IL-1 is not a primary disease driver, but rather a molecule that 
sustains inflammation, downstream of IL-36 [161]. 
More recently, IL-17A antagonists have shown some efficacy in GPP, however this result was obtained 
in small trials with no placebo arm [162], [163]. 
Finally, given the findings presented on this thesis and prior evidence of IL-36 role in GPP, IL-36 
blockade showed to be a possible therapeutic target. Interestingly, recently published data on IL-36 
blockade in GPP patients describes it as promising [164]. 
Such progress demonstrates the translational potential of genetic studies and underscores the need 







The aim of this study was to investigate the mechanisms underlying IL-36 driven inflammation, with a 
particular focus on psoriasis. Thus, the intermediate objectives of the project were: 
  
 To define a transcriptional signature of IL-36 activation, through the RNA-sequencing of IL-36 
stimulated cells. This experiment was implemented in keratinocytes, based on the robust 
expression of IL-36R in these cells. After the presence of the signature was validated in the Ps 
and GPP skin transcriptomes, its biological significance was explored by means of pathway 
enrichment analysis. 
 
 To investigate the pathogenic role of IL-36 signalling at the systemic level. Given the 
prominence of systemic symptoms and IL-36 up-regulation in GPP, the study mainly focused 
on this condition. The effects of IL-36 on circulating immune cells were defined through the 





3 Materials and Methods 
3.1 Materials 
Reagent Manufacturer Catalogue number 
1X KAPA SYBR FAST Universal qPCR Master Mix Primerdesign 
 
n/a 
CD3 Isolation kit Miltenyi Biotech 130-050-101 
CFSE tracker BioLegend 423801 
CpG ODN-2216 INVIVOGEN tlrl-2216 
dNTP nucleotides Fisher Scientific 10520651 
Dulbecco’s Modified Eagle Medium (DMEM), high 
glucose, GlutaMAX™ Supplement 
Gibco 61965026 
Dynabeads™ Human T-Activator CD3/CD28 Thermo Scientific 11132D 
Ethanol VWR 20821.330 
Ficoll GE 17544202 
Fixation & Permeabilization kit Thermo Scientific GAS003 
Foetal Bovine Serum (FBS) Gibco 10500064 
GeneJET RNA Purification Kit Thermo Scientific K0731 
GLOBINclear™ Kit Life Technologies AM1980 
Glutamax RPMI Gibco 61870010 
Human IFN-alpha ELISA kit Bio-Techne 41100-1 
IL36-α Bio-Techne 6995-IL-010/CF 
Neutrophils isolation kit Miltenyi Biotech 130-104-434 
PBS Gibco 10010015 
Penicillin-Streptomycin Gibco 15140122 
Plasmacytoid Dendritic Cell Isolation Kit Miltenyi Biotech 130-097-415 
Precision nanoScript2 Reverse Transcription kit PrimerDesign n/a 
PrecisionPlus SYBR and ROX qPCR Mix PrimerDesign n/a 
Recombinant Human IL-36 alpha/IL-1F6 (aa 6-
158) Protein 
R&D Systems 6995-IL-010 
RNA buffer Agilent 5067-5577 
RNA ladder Agilent 5067-5578 
RNA screen tape Agilent 5067-5576 
RNaseZap™ RNase Decontamination Solution Invitrogen AM9780 
RPMI 1640 Medium Gibco 21875034 
Tempus™ Spin RNA Isolation Kit Thermo Scientific 4380204 
Tryphan blue Gibco 15250061 
β2M PrimerDesign probe PrimerDesign 54684 




3.2 Study resources 
This research was carried out in accordance with the principles of the Declaration of Helsinki. The 
majority of cases (n=31) were recruited as part of the PLUM (Pustular psoriasis: eLucidating Underlying 
Mechanisms) study, which was approved by the London - London Bridge Research Ethics Committee 
(reference 16/LO/2190, 30th January 2017). A further 5 affected individuals were ascertained through 
the APRICOT (Anakinra for Pustular psoriasis: Response in a Controlled Trial) clinical trial, which was 
granted ethical approval on 1st April 2016 and assigned EudraCT number 2015-003600-23. The ethics 
committees of collaborating institutions also granted the required approvals. On this basis, 9 GPP 
patients (1 male and 8 females, average age: 57) and 7 controls (1 male and 6 females, average age 
52) were ascertained for whole-blood RNA-seq. A further 35 cases (10 males, 25 females, average age: 
49) and 7 controls (6 females and 1 male, average age: 45) were recruited for validation studies (Tables 
3.1.1 and 3.1.2). Blood was also obtained from 4 cases (1 male and 3 females, average age: 47.3) and 
4 controls (3 females, and 1 male, average age: 33.4 or 36.6) for flow-cytometry (Tables 3.2.1 and 
3.2.2) and in-vitro assays. Finally, samples donated from 3 healthy volunteers (1 male and 2 females, 
average age: 29 or 27.6) were used for stimulation of peripheral blood mononuclear cells (PBMCs) or 
pDCs (see section 3.3). 
All cases were diagnosed by expert dermatologists, based on the appearance of macroscopically 
visible sterile pustules on non-acral skin [138]. While some patients suffered from concomitant plaque 
psoriasis, the presence of pustules that were restricted to the edges of psoriatic plaques was 
considered an exclusion criterion. Details of patient demographics and clinical presentation were 
recorded in a standardised Case Report Form.  
The patients were ascertained at St John’s Institute of Dermatology (London), Glasgow Western 
Infirmary, Manchester University and Hospital Sultanah Aminah, Johor Bahru, Malaysia. The healthy 
controls were recruited from the personnel of St John’s Institute of Dermatology. All study participants 




Table 3.2. 1. Demographics and clinical characteristics of the affected individuals 
Patient 
ID 




History of systemic 
Inflammation1 




T029045 European F 10 N Y (Fever, Neutrophilia, 
Elevated CRP) U 
WT 48 RNAseq 
T028820 European F 11 Y Y (Elevated CRP) U p.S113L/- 47 RNAseq 
T029060 European M 5 N Y (Neutrophilia, Elevated 
CRP) No treatment 
p.S113L/- 43 RNAseq 
T031013 European F 7 N Y (Fever, Neutrophilia) Infliximab p.R48W/p.S113L 46 RNAseq 
T026307  European F 5 N Y (Fever, Neutrophilia, 
Elevated CRP) Methotrexate 
WT 88 RNAseq 
T031359 European F 45 N 
Y (Fever, Elevated CRP) 
Infliximab/ 
Methotrexate 
WT 90 RNAseq 
T031360 European F 51 N Y (Fever, Elevated CRP) Acitretin p.S113L/p.S113L 65 RNAseq 




WT 47 RNAseq 




WT 38 RNAseq 
T031846 
 




















































































































































U U U U U U U 28 Validation 
qPCR 
T031590 Asian F 31 N N Infliximab WT 50 Flow 
cytometry 




Asian F 30 Y U U WT 31 Flow 
cytometry 
T028820 European F 42 Y Y Infliximab p.S113L/- 51 Flow 
cytometry 
1Fever is reported if >38C, elevated CRP= CRP>100mg/L 




Table 3.2. 2. Demographics of the healthy individuals used as controls 
Study number Ethnicity Sex  Age at recruitment Analysis group 
T031200 European F 45 RNAseq 
T031201 European M 55 RNAseq 
T031202 European F 48 RNAseq 
T031203 European F 49 RNAseq 
T031221 European F 52 RNAseq 
T031222 European F 62 RNAseq 
T031556 European F 53 RNAseq 
T039111 European F 39 Validation qPCR 
T039113 European F 49 Validation qPCR 
T039129 European F 63 Validation qPCR 
T039346 Asian F 38 Validation qPCR 
T039224 European F 35 Validation qPCR 
T039226 European M 36 Validation qPCR 
T031558 European F 52 Validation qPCR 
GYPLM0071 European F 30 Cells stimulation, flow cytometry 
GYPLM0037 European M 26 Cells stimulation, flow cytometry 
GYPLM0048 European F 26 Cells stimulation 
GYFAP0179 Finnish F 31 Cells stimulation, flow cytometry 
GYPLM0026 European F 30 Flow cytometry 
GYPLM0017 European F 50 Flow cytometry 






3.3 Transcription profiling 
3.3.1 Retrieval of publicly available datasets 
The Gene Expression Omnibus (GEO) and ArrayExpresss (https://www.ncbi.nlm.nih.gov/gds and 
https://www.ebi.ac.uk/arrayexpress/) databases were queried using the “tissue”, ”date” and 
“experiment” search fields, in order to identify transcriptome studies (RNAseq, microarray) performed 
on whole blood, no later than December 2015. This search uncovered four datasets including 
individuals affected by cryopyrin-associated periodic syndrome (CAPS), interferonopathies or plaque 
psoriasis (Table 3.3.1). Raw counts or fastq files were downloaded and analysed using the in-house 
pipeline described in the following sections.  
The 10KImmunome [165] dataset (whole blood transcriptome profiles for 221 healthy individuals. 110 
males and 111 females, average age: 31, ethnicity: 44 Asian, 126 White, 25 Black and African 




Table 3.3. 1. Study resources 
Dataset ID Dataset Cohort Reference 
GSE55201, GEO DataSets Ps, whole blood 33 cases, 44 healthy controls Wang CQF, et al. J Invest Dermatol 2014 [166, p. 17] 
n/a; data provided by the authors CANDLE, whole blood 3 cases, 5 healthy controls  Brehm A., et al. JCI 2015 [19]  
E-MTAB-5735 type I interferon-mediated 
autoinflammation, whole blood 
8 cases, 5 healthy controls Rodero MP., et al. Nat Commun 2017 [167]  
GSE57253, GEO DataSets NOMID, whole blood 7 cases, 11 healthy controls  Canna SW., et al. Nat Genet 2014 [168] 
GSE67785, GEO DataSets Ps, skin 14 paired lesional and non lesional 
skin biopsies 
Swindell, W. R., et al. Genome Med 2015 [169]  
GSE59275, GEO DataSets IL-4 treated keratinocytes 3 replicates of treated and  
untreated keratinocytes 
Only available through GEO Datasets 
n/a; data downloaded from: 
http://10kimmunomes.ucsf.edu/ 
Human whole blood 
transcriptome 





3.3.2  RNA isolation and sequencing 
Three ml of whole blood were obtained from each study participant and stored at -80C in a Tempus™ 
Blood RNA Tube. Total RNA was isolated using a Tempus™ Spin RNA Isolation Kit, according to the 
manufacturer’s instructions. Samples were then diluted in a final volume of 50 μl of RNAse free water. 
Samples were subject to globin depletion using a GLOBINclear™ Kit and quantified with a Qubit 4 
fluorometer (Thermo Fisher Scientific). RNA integrity numbers (RIN) were measured with a 
Tapestation 4200 (Agilent Genomics). RIN were higher than 7 in all samples.  
RNA-seq libraries were prepared with the Illumina TruSeq Stranded polyA RNA preparation kit and 
sequenced on an Illumina HiSeq 3000 system at the Next Generation Sequencing Facility, Leeds 
Institute of Molecular Medicine, University of Leeds. Data were provided as fastq files and analysed 





3.3.3 Differential expression analysis 
3.3.3.1 RNAseq analysis 
The quality of the sequence data was assessed using FastQC and reads with a Phred score<30 were 
excluded from further analyses. The reads that passed this step were trimmed and overrepresented 
sequences were removed using FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). The 
alignment was performed against the HG38 human genome using TopHat [170], with indexes 
generated by Botwie2 and reports by samtools [171]. Finally, the reads aligning to each gene were 
counted, using HTseq-count (--nonunique union, --idattr=gene_id).  
Read counts were used as input for the differential expression analysis. This was performed using 
DESeq2 (R package, v 16.2, [172]). The underlying methodology may be summarised as follows: read 
counts for each gene are described with a generalised linear model (GLM) of the negative binomial 
family. The model uses the mean read counts per gene per sample, normalised with a sample-specific 
constant that takes into account the total number of reads obtained in each sample. The mean 
normalised gene counts are used to estimate gene dispersion and compute a trend. Gene specific 
dispersion is then fitted to the trend using the GLM model and taking into account within-group 
variability. At this stage, confounding factors can also be added to the equation as covariates.   
Fold changes are computed postulating a zero-centred normal prior, meaning that the distance of 
each gene from the fitted trend is the measure of the differential expression of the contrast group. 
Finally, the P values are calculated using the Wald Test and then corrected for multiple testing using 





3.3.3.2 Microarray analysis 
The analysis of microarray data was undertaken with the limma package [174], which is based on a 
linear model. A correction is first performed to subtract the background noise from the foreground 
intensity of each spot. Signals are then normalised using Robust Multichip Average (RMA) 
normalization methods, and converted into expression measures. Two matrices are built: the design 
(to specify contrast groups) and the coefficient matrix. Each row of the design matrix corresponds to 
an array in the experiment and each column corresponds to a coefficient that is used to describe the 






3.3.4 Enrichment analyses 
3.3.4.1 Pathway enrichment analysis 
After differential expression analysis, genes with an absolute fold change (FC) ≥1.5 and a false 
discovery rate (FDR) <0.05 were used as input for Ingenuity Pathway Analysis (IPA, Qiagen). Briefly, 
the software first ranks the genes based on FC and then assigns a weight to each feature. Input genes 
are then mapped against reference pathways and an enrichment P value is computed with an exact 
Fisher’s test, taking into account the size of the pathway and the weight of differentially expressed 
genes. P values are then corrected for multiple testing using the Benjamini-Hochberg method. 
3.3.4.2 Transcription Factor Activity 
TF activity analyses was also performed using IPA software, using the Upstream Analysis option. The 
algorithm considers the dataset as a subgraph with a priori unknown causal edges in the master 
network. In order to identify them, all the genes are considered as potential regulators and they are 
scored for downstream targets identified. The downstream targets are defined by an enrichment P 
value assuming a random dataset with a constant number of genes as null model. To each network is 
then associated an activation score based on co-expression values. Finally, the enrichment of each 
network in the dataset is computed [176].  
3.3.4.3 Transcriptional Module enrichment 
The script published by Li et al. [177] was slightly modified, in order to identify blood transcriptional 
modules that are enriched in the GPP transcriptome. Briefly, the modules that were active in our 
dataset were selected using the genetable_to_activityscores function. Next, the enrichment_test 
function was applied to our list of differentially expressed genes, taking into account the module 
activity scores and fold change of the genes mapping to each module. Enrichment P values were then 




3.3.4.4 Cytokine scores 
The interferon score has been previously defined and used by others [178] as an indirect measure of 
type-I-IFN production. Here, five interferon stimulated genes (ISGs: IFI6, IFIT3, IFITM3, OASL and 
PLSCR1) were identified by cross-referencing the most up-regulated loci in GPP blood with the type I 
IFN targets reported in the Interferome database [179]. Since the genes that are induced by IL-36 have 
not been characterised in leukocytes, the IL-36 signature was defined by using genes that were i) up-
regulated in KCs stimulated with IL-36 [180] and ii) expressed in blood (IL1B, PI3, VNN2, TNFAIP6 and 
SERPINB1). For both measures, the expression of the five signature genes was normalised against a 
calibrator and scores were computed in each individual, as the median normalised expression of the 
five genes.  
3.4 Cell culture and stimulation 
3.4.1 Cell isolation 
Blood (20 ml) was collected from healthy volunteers and peripheral blood mononuclear cells (PBMCs) 
were isolated by density centrifugation on 15 ml of Ficoll, in the absence of red blood cells lysis. Cells 
were counted on a Marenfield superior haemocytometer and seeded in 48-well plates, at a density of 
2.5x106cells per well. 
Plasmacytoid dendritic cells (pDCs) were purified from PBMCs using a Plasmacytoid Dendritic Cell 
Isolation Kit (Miltenyi Biotec) and cultured at a density of 2.5x105 cells/ml. 
T cells were isolated using a CD3 Isolation kit (Miltenyi Biotec) and cultured at a density of 1.5x106 
cells/ml. Cells were labelled with CFSE tracker (BioLegend) at time zero and stimulated with 





3.4.1 Cell culture 
All cells were grown under aseptic conditions in a NUAire Air-Jacketed Automatic CO2 (NU-5500) 
incubator at 37C and 5% CO2.  
Freshly isolated cells were incubated overnight in Glutamax RPMI supplemented with 10% FBS and 
5% P/S (Penicillin/Streptomycin Solution). The next morning the cells were stimulated with 50ng/ml 
IL36-α for 6 hours and then with 1.6μg/ml of ODN-A CpG (or vehicle) for a further 6 or 12 hours. 
Cells were then harvested and used for FACS assays or centrifuged at 3000 rpm for 7 minutes. 
Supernatants and cell pellets were stored at -80C for use in ELISA or RNA extraction, respectively. 
Each experiment was performed at least three times, in three technical replicates. 
3.4.2 Quantitative real-time PCR 
Prior to RNA extraction, all surfaces and pipettes were treated with RNaseZap RNase Decontamination 
Solution. RNA was extracted from whole blood using Tempus™ Spin RNA Isolation Kit and from PBMCs 
using the GeneJET RNA purification kit. RNA was eluted in 50 and 30 μl of RNase-free water, 
respectively. Samples were quantified using Qubit 4 fluorometer (Invitrogen) and stored at -80°C. 
For each experiment, 100-200ng of RNA were reverse-transcribed with a nanoScript2 kit. The 
reactions were incubated at 25°C for 10 minutes, 37°C for 120 minutes and 85°C for 5 minutes. After 
the reverse transcription was completed, the cDNAs were diluted by adding 30 μl of nuclease-free 
water to each reaction.  
Gene expression was assessed using the primers listed in Table 3.4.1. Primers were designed using 
Primer3 web version 4.1.0 [181]. Reactions were set up to a final volume of 20μl containing 70nM of 
primers, 1X KAPA SYBR FAST Universal qPCR Master Mix and 2μl of cDNA.  
Samples were loaded on a 7900HT Fast Real Time PCR System (Applied Biosystem) and the cycling 




Transcript levels were normalised using B2M expression and relative gene expression was quantified 
using the ΔΔCt method [182]. 
Table 3.4.1. Primers used for the real time PCR 
Target gene Primer name Sequence 
IFI6 IFI6-R TTTCTTACCTGCCTCCACCC 
IFI6-F CCATCTATCAGCAGGCTCCG 
IFIT3 IFIT3-R TTGGTGACCTCACTCATGATGG 
IFIT3-F GCACAGACCTAACAGCACCC 
IFITM3 IFITM3-R CACTGGGATGACGATGAGCA 
IFITM3-F TCGCCTACTCCGTGAAGTCTA 
OASL OASL-R GGAACCTGGAAGGACAGACG 
OASL-F GTACCAGCAGAGGGCACG 
PLSCR1 PLSCR1-R AGGAGGATACCCAACTGGCA 
PLSCR1-F CGGCAGCCAGAGAACTGTTTTA 






The production of IFN-α was measured with the Human IFN-α ELISA kit. Supernatants were diluted 
1:10 and analysed in duplicated. The absorbance at 450nm was determined using an ELISA FLUOstar 






3.5 Flow cytometry 
PBMCs and T cells were isolated from 20ml blood samples obtained from four healthy controls. 
Neutrophils were purified from four ml blood samples (n = 3 healthy volunteers), using the 
MACSxpress Neutrophil isolation kit. pDCs were purified from freshly isolated PBMCs (n = 3 healthy 
volunteers). pDCs, PBMCs and neutrophils were seeded in five ml round-bottom polystyrene tubes at 
a density of 105 cells/100μl , 2.5x106cells /100μl and 1x106cells /100 μl, respectively. Cells were 
washed with two ml PBS before centrifugation at 1800 rpm for 5 minutes.  
For live cell detection, LIVE/DEAD™ Fixable Near-IR was added at a 10nM final concentration. Cells 
were then incubated with the dye at 4° for 15 minutes. After a PBS wash Monocytes and Fc blocker 
(1:40) was added for 20 minutes. PBMCs were washed and treated with two different combination 
(panels) of antibodies (Table 3.5.1), in order to identify the various leukocyte populations that were 
present in the sample. All incubations were performed in the dark. Neutrophils were stained for 
Lineage cocktail, CD15, CD16 and CD14. T cells were stained for CD3, CD4 and CD8.  
For IFN-α and PLSCR1 detection, cells were fixed using a Fixation & Permeabilization kit prior to 
intracellular staining. In all experiments, cells were incubated for 20 minutes at 4° with the relevant 
antibody and then washed in PBS (for surface staining) or Perm buffer (for intracellular straining). 
When needed, the secondary antibody was added for 20 minutes at 4°; cells were then washed and 
re-suspended in 300μl of PBS or Perm buffer, as appropriate. 
Cells were analysed on a BD Fortessa LSR machine, collecting 105 events. Data were analysed using 




Table 3.5.1. Flow Cytometry Antibodies 
Antibody Cat Number Colour Provider Diluition1 Application 
CD16 48-0168-42 Efluor450 ThermoFisher  1:20 Panel 1 / Neutrophils 
CD56 318316 Alexa Fluor 700 BioLegend 1:33 Panel 1 
CD19 302242 BV510 BioLegend 1:20 Panel 1 
CD20 130-096-649 PE-Cy7 Miltenyi 1:33 Panel 1 
CD14 555398 PE BD 1:20 Panel 1 / Neutrophils 
CD3 317306 FITC BioLegend 1:33 Panel 1/T cells 
CD127 351320 PE-Cy7 BioLegend 1:20 Panel 2 
HLA-DR 307636 BV421 BioLegend 1:33 Panel 2/pDCs 
CD11c 301638 BV650 BioLegend 1:20 Panel 2/pDCs 
CD123 306030 BV711 BioLegend 1:30 Panel 2/pDCs 
Lineage Cocktail 2 B29559 PE Beckman Coulter 1:10 Panel 2 
CD15 301904 FITC BioLegend 1:33 Neutrophils 
IL1RL2 BAF Streptavidin BD 1:10 Panel 1/ 2 and Neutrophils 
Biotinylated 
secondary Antibody3  




PLSCR1 ab180518 Rabbit-IgG Abcam 1:50 Panel 1/ 2 and pDCs 
Rabbit IgG4 406416 Alexa Fluor 488 BioLegend  1:100 Panel 1/ 2 and pDCs 
IFN-α 130-092-602 APC  Miltenyi Biotec  1:10 Panel 1/ 2 and pDCs 
CD4 357424 BV421 BioLegend 1:33 T cells 
CD8 555750 PE-Cy5 BioLegend 1:33 T cells 
1Final volume = 100 μl 










Fig 3.5.1 Gating Strategy 
(A) General gating strategy applied to all the samples in which debris, doublets and dead cells are 
removed. (B) Dendritic cells (DCs) are gated as HLA-DR+ Lineage- cells and then separated into pDCs 
and myeloid dendritic cells (mDCs), based on CD123 and CD11c expression. (C) Innate lymphoid cells 
(ILCs) are gated as CD127+ Lineage- cells. (D) Neutrophils are gated as CD16+ CD14- CD15+ cells. (E) 
Monocytes are selected as CD56-, CD20-, CD3-, CD19- cells and then separated into pro-inflammatory 
(CD16high CD14-), intermediate (CD16+ CD14+) and classical (CD16- CD14+) subtypes. (F) B cells are 
selected as CD14- and CD16- cells, and successively gated for CD19 and CD20. (G)T cells are CD3+, CD20, 





4 IL-36 cytokines have a key role in the 
pathogenesis of psoriasis 
4.1  IL-36α, -β and -γ induce similar signature genes in keratinocytes  
To achieve a better understanding of IL-36 activity in psoriasis, IL-36 signature genes were defined by 
expression profiling of primary keratinocytes (KCs). 
KCs isolated from healthy donors were treated with IL-36, - or -γ for 24h. RNA was then isolated 
from technical replicates (n=3 for each condition) and sequenced. On average 24.5 million reads were 






Table 4.1.1. RNAseq coverage statistics 
   Mean read count per gene 
  Sample description Mapped  
paired-end reads 
Mapping rate Raw count Normalised count 
  
IL-36α treated KCs 
  
replicate-1 23,920,393.00 95.00% 612.44 639.59 
replicate-2 24,318,945.00 95.30% 612.50 632.08 
replicate-3 25,239,033.00 95.10% 646.79 631.58 
  
IL-36β treated KCs 
  
replicate-1 23,068,715.00 95.10% 591.21 609.28 
replicate-2 24,188,385.00 95.00% 616.96 619.65 
replicate-3 21,578,713.00 95.00% 552.08 622.24 
  
IL-36γ treated KCs 
  
replicate-1 26,137,519.00 95.00% 670.96 660.01 
replicate-2 25,336,550.00 95.50% 650.79 661.20 




replicate-1 26,001,336.00 95.20% 663.49 614.60 
replicate-2 25,479,797.00 95.20% 657.08 626.87 






Principal component analysis (PCA) of normalised read counts showed a very clear separation 
between untreated and treated KCs. Conversely, the three groups of stimulated KCs clustered very 
close to each other (Fig. 4.1.1 A). This pattern was confirmed by hierarchical clustering analysis 








Fig. 4.1.1. Features of IL-36α, -β and -γ transcriptomes in keratinocytes. 
(A) PCA showing that untreated keratinocytes cluster separately from the treated ones. Cultures were 
stimulated in triplicate, so each dot represents a technical replicate. (B) Heatmap generated using 
unsupervised clustering algorithm from normalised expression values (RPKM) showing differences and 





A comparison of treated and untreated samples demonstrated that 4,096, 4,459, and 3,468 genes 
were differentially expressed [false discovery rate (FDR), <0.05] upon treatment with IL-36α, IL-36β, 






Fig. 4.1.2. Differentially expressed genes in keratinocytes treated with IL-36 cytokines. 
Volcano plot showing differentially expressed genes in KCs treated with IL-36α,β or ɣ (from top left, 
respectively). Black dots represent genes differentially expressed at FDR < 5% and absolute log2 FC ≥ 
1.5. Names for the most up-regulated genes are reported. Red labels indicate the genes validated by 






Only a small number of genes were specifically up-regulated by IL-36α or γ (n=3 and 5, respectively). 
Conversely, 112 of the 352 genes (31.8%) that were induced by IL-36β were only up-regulated by this 
cytokine. These unique targets included several long non-coding and antisense RNAs, suggesting that 
IL-36β may drive important regulatory circuits in skin. 
Overall, a substantial overlap between the three datasets was observed, as 182 genes (referred to as 







Fig. 4.1.3. Identification of IL36_182 gene set. 
Venn diagram showing the overlap between genes that are up-regulated by IL-36α (orange), β (green) 





The IL36_182 set includes genes that were previously known to be IL-36 regulated (CCL20, CXCL1, IL8, 
DEFB4A, STEAP4) [183], as well as novel targets such as the phospholipase PLA2G4D, which is involved 
in lipid antigen presentation by Langerhans cells [27]. Furthermore, an interesting up-regulated gene 
shared by the three dataset is OASL. This gene is involved in antiviral response and production of type-
I IFN. In fact, this cytokine plays a key role in inflammation and in psoriasis as previously described [74] 






4.2 IL-36 is a dominant cytokine in the GPP and Ps skin transcriptomes  
Having identified a set of IL-36 signature genes, the next step was to establish whether these were 
enriched within the GPP and Ps transcriptomes. Two publicly available datasets were examined: a GPP 
microarray resource (based on the analysis of skin biopsies obtained from 30 cases and 20 healthy 
controls) and a Ps RNAseq study (based on the analysis of 44 Ps and 30 control skin samples) [169], 
[184]. 
As expected for an IL-36 driven disease, the analysis of the GPP resource revealed a significant overlap 
with the IL36_182 set (P<10-15), as 58 genes were up-regulated by IL-36 and robustly over-expressed 
in patient skin (Fig. 4.2.1). Of note, a similar enrichment was observed in the Ps dataset, with 68 of the 
IL36_182 loci found to be highly over-expressed in patient skin (P<10-15) (Fig. 4.2.1).  
To further validate these results, the transcriptome of KCs treated with IL-4 (an irrelevant Th2 
cytokine) was analysed as a negative control. As expected, the gene set induced by IL-4 did not 






Fig. 4.2.1.The IL36_182 set significantly overlaps with genes up-regulated in GPP or Ps. 
 
Venn diagrams showing the overlap between the IL36_182 set (purple) and the 500 genes that are 
most significantly up-regulated genes in GPP (red) or Ps (blue). The 10 IL-36_182 genes that show the 






Fig. 4.2.2. IL-4 signature genes do not overlap with the Ps or GPP transcriptome 
Intersection between the IL36_182 set and genes that are up- (FDR < 0.05, log2 Fold Change > 2) or 
down- (FDR < 0.05, log2 Fold Change < -2) regulated by IL-4 in keratinocytes. The P values under each 





4.3 IL-36 induced genes are enriched within Ps susceptibility loci 
To explore the possibility that IL-36 induced genes may be genetically linked to psoriasis, their overlap 
with psoriasis susceptibility loci previously identified by Genome Wide Association Studies (GWAS) 
was examined. 
Interestingly, this analysis demonstrated that the IL36_182 set was significantly enriched among the 
genes lying within psoriasis associated regions (P=9.1x10-4). To further support these findings, genes 
associated with schizophrenia or autism were investigated as negative controls. As expected, no 
significant overlap was observed between IL-36 induced genes and the susceptibility loci for the above 








Fig. 4.3.1. Members of the IL36_182 set are over-represented within psoriasis susceptibility 
intervals. 
Bar chart showing the over-representation of the IL36_182 set among genes lying within Ps 
susceptibility regions detected in GWAS. Schizophrenia and autism susceptibility intervals were 





4.4  IL-36 signature genes cluster to pathways implicated in the 
pathogenesis of psoriasis 
The following phase of this study aimed to link the IL36_182 genes to their biological function. To this 
end, pathways analyses were performed using IPA. This identified 58, 54 and 63 enriched pathways 
(FDR < 0.05) in KCs stimulated with IL-36α, -β or -γ, respectively.  
Interestingly, the number of pathways that were associated with a single cytokine was very low (3, 3 
and 2 for IL-36α, -β and –γ, respectively), with the majority (45/63) showing an enrichment in all three 
transcriptomes (Fig 4.4.1) (Appendix A). 
The most substantially enriched pathway was Role of IL−17A in Psoriasis (FDR <10−10in all three 
datasets) with significant FDR values also observed for several processes related to inflammation. 
These included Acute Phase Response Signalling (FDR <10−5), Communication between Immune Cells 
(FDR <10−5), Toll-like Receptor Signalling (FDR <10−5) and Granuocyte/Agranulocyte Adhesion in 






Fig. 4.4.1. There is a substantial overlap between the pathways that are enriched in the IL-36α, -β 
and -γ transcriptomes. 
Venn diagram showing the intersection of the pathways that are enriched (FDR<0.05) in the three IL-








Fig. 4.4.2. The biological pathways driven by IL-36α, -β and -γ are relevant to the pathogenesis of 
psoriasis. 
Pathway enrichment analysis demonstrates that processes related to psoriasis, e.g. IL-17 signaling and 
leukocyte recruitment, are over-represented in the IL-36α, -β and -ɣ transcriptomes. The red dotted 





To further investigate these findings, a pathway analysis was also performed for the genes that are 
up-regulated in Ps and GPP. This uncovered 71 enriched pathways in Ps and 48 in GPP. Of note, both 










Fig. 4.4.3. IL-36 induced genes map to pathways related to psoriasis. 
The Venn diagram shows the intersection between the pathways that are enriched in Ps (blue) or GPP 
(red) and in the three IL-36 transcriptomes (purple). The 10 most significantly enriched pathways are 





4.5 Validation of selected IL-36 target genes 
To validate the effect of IL-36 cytokines on downstream genes, keratinocytes were obtained from 
three additional healthy donors. Following stimulation with IL-36, - or -, the expression of genes 
mapping to pathways enriched in Ps skin (highlighted in red in Fig 4.1.2) was examined. The analysis 
specifically focused on key loci related to Role of IL-17A signalling in psoriasis (IL36G, S100A7 and 
LCN2); Granulocyte/agranulocyte adhesion and diapedesis (CCL20, IL8 and MMP9) and p38 MAPK 
signalling (IRAK2 and PLA2G4D). 
Real-time PCR confirmed that IL-36 cytokines up-regulated all examined genes. The effect was 
particularly pronounced for S100A7 (FC >50) and IL36G (FC > 8.5) (Fig 4.5.1). Thus, the up-regulation 







Fig. 4.5.1. Validation of up-regulated genes in keratinocytes obtained from independent healthy 
donors. 
mRNA induction of key genes was measured by real-time PCR, using B2M as an endogenous control. 
Within each experiment, gene expression measurements were normalised to the transcript levels 
observed in the untreated sample (-). Data are presented as mean +/- SD of technical duplicates. Each 
bar represents one of the three independent donors. *P < 0.05, **P < 0.01, ***P ≤ 0.001, ****P ≤ 







The aim of these experiments was to investigate the role of IL-36 cytokines in the pathogenesis of 
psoriatic skin inflammation.  
Several transcriptomic studies have been performed on Ps skin. These repeatedly showed a significant 
up-regulation of IL-36 cytokines, with one study also reporting a correlation between serum IL-36 
levels and psoriasis severity [185].  
Furthermore, it has been shown that IL-36 has marked pro-inflammatory effects in three-dimensional 
skin cultures and in mouse models of psoriasis [73], [186], [187]. However, the mechanisms whereby 
IL-36 up-regulation may contribute to the pathogenesis of Ps have not been fully investigated. The 
aim of this part of the study was to fill this knowledge gap, by harnessing the power of expression 
profiling. 
The first step was to define an IL-36 signature that could be used to interrogate Ps and GPP 
transcriptome datasets. 
Following treatment of KCs with IL-36α, -β or –γ, marked similarities were observed between the 
genes that were induced by the three cytokines. Interestingly, this observation was recently confirmed 
in two independent studies of IL-36 treated KCs [155], [188]. These also shed new light on the 
mechanism that mediates IL-36 signal transduction, showing a requirement for MyD88 and IκBζ, an 
atypical member of the IκB family [189].  
Of note, the differential expression analysis identified a number of genes that were uniquely induced 
by IL-36β. Given that the majority of these were non-coding or antisense transcripts, it is tempting to 
speculate that this cytokine may also play a role in the broader regulation of skin immune 
homeostasis. In fact, accumulating evidence suggests that lncRNAs are important modulators of the 
inflammatory response [190]–[193]. Carpenter et al, for example showed that the up-regulation of a 




of skin inflammation, Tsoi et al. identified more than 3,000 human, skin-specific lncRNAs, many of 
which are co-expressed with immune genes [195]. Thus, it would be interesting to investigate whether 
the expression of IL-36-dependent lncRNAs correlates with that of innate immune genes that 
contribute to KC inflammatory responses. 
Following the identification of differentially expressed genes, pathway enrichment analyses were 
undertaken to investigate the biological processes that are driven by IL-36 cytokines. This identified a 
very significant over-representation of genes related to Role of IL-17A in Psoriasis.  
IL-17 is a key disease driver in Ps, as demonstrated by the therapeutic efficacy of the biologics that 
inhibit its action [196]–[198]. The cytokine is produced by Th17 cells, a T lymphocyte sub-population 
that differentiates from naïve T-cells exposed to IL-23 [199]. The latter can be secreted by DCs and 
Langherans cells responding to IL-36 [61], [68]. Thus, IL-36 indirectly promotes IL-17 production by 
driving the activation of DCs. IL-17, in turn, acts on KCs by inducing the expression of further IL-36 
[200]. Therefore, the data presented here supports the existence of a positive feedback loop, driven 
by the reciprocal up-regulation of IL-17 and IL-36 (Fig. 4.6.1).  
IL-36 also contributes to this inflammatory circuit by up-regulating various important chemokines 
which recruit neutrophils (IL8, S100A7) and Th17 cells (CCL20) to sites of inflammation (Fig. 4.6.1).  
Thus, the analyses described in this chapter demonstrated that IL-36 cytokines drive inflammatory 
pathways which sustain and propagate inflammation in Ps skin. Of note, follow-up work carried out 
by other members of the Capon lab showed that IL-36 blockade has profound anti-inflammatory 
effects in an animal model of psoriasis (imiquimod-induced psoriasiform dermatitis), where it reduces 
epidermal thickness and leukocyte infiltration [201], [202]. Similar results were obtained by other 







Fig. 4.6. 1.IL-36 enhances skin inflammation by sustaining IL-17 production. 
IL-36 cytokines, produced by keratinocytes following trauma or infection, act on dendritic cells and 
Langerhans cells (via PLA2G4D), resulting in the polarization of Th17 lymphocytes. These release IL-
17, which in turn promotes further IL-36 production by keratinocytes.  





5 The Role of IL-36 in systemic inflammation, a 
transcriptomic approach 
5.1 The whole blood transcription profiles of GPP patients are very 
heterogeneous 
The aim of the second part of the study was to investigate the role of IL-36 cytokines in the systemic 
pathogenesis of psoriasis. GPP was selected as the initial focus of the investigation given that it 
manifests with overt systemic symptoms and has been genetically linked to abnormal IL-36 activity.  
Whole blood obtained from nine GPP patients and seven healthy individuals was subjected to RNA-
sequencing, with a view to determine which transcriptional pathways are disrupted in a condition 
caused by abnormal IL-36 signalling.  
After assessing the quality of the sequence data (Table 5.1.1), raw counts were obtained for ~21,000 
genes, including protein coding and non-coding antisense transcripts. In order to visualise this 
information, dimensionality reduction algorithms were applied. Principal Component Analysis (PCA) 
showed that the GPP transcriptome is very heterogeneous compared to that of the control group, 
which forms a better defined cluster (Fig. 5.1.1). 
An analysis of possible confounders showed that patients did not cluster by ethnicity, age, mutational 
status or treatment. In contrast, gender clearly discriminated data distribution along the first two 
principal components (Fig. 5.1.1) and was therefore included as a covariate when computing 




Table 5.1.1. Whole-blood RNAseq statistics. 
Sample Number of paired 
reads 
Mapping rate Median raw 
counts per gene 
Median RPKM per 
gene 
C1 15,100,000 95% 54 82.47 
C2 19,200,000 98% 73 74.87 
C3 19,900,000 98% 92 77.99 
C5 19,600,000 98% 88 81.36 
C7 18,200,000 98% 87 82.69 
C8 20,800,000 97% 98 74.05 
C9 18,600,000 95% 84 82.83 
GPP1 18,200,000 95% 68 86.31 
GPP2 14,800,000 92% 33 87.32 
GPP3 19,300,000 88% 59 71.65 
GPP4 19,600,000 95% 77 82.00 
GPP5 20,200,000 95% 75 87.09 
GPP6 21,500,000 95% 58 88.55 
GPP7 23,200,000 98% 97 88.18 
GPP8 21,200,000 95% 93 82.45 







Fig. 5.1.1. Principal component analysis (PCA) of whole-blood RNA-seq data 
PCA showing the position of GPP cases (triangles) and healthy individuals (circles). While control 
samples tend to cluster together, they also overlap with some of the cases. In contrast, males (blue) 





5.2 IL-36 signalling is systemically up-regulated in GPP patients, regardless 
of mutation status 
Only three of the nine patients who were RNA-sequenced harboured IL36RN mutations, reflecting the 
prevalence of IL36RN disease alleles in patient cohorts (25-30%) [143]. In this context, it was important 
to establish that abnormal IL-36 signalling was present in all nine cases.  
Five genes that are strongly up-regulated by IL-36 and robustly expressed in whole-blood (IL1B, PI3, 
VNN2, TNFAIP6 and PLSCR1) were analysed, in order to derive a transcriptional signature of IL-36 
activation. Of note, none of the selected genes are up-regulated in the whole-blood of patients 
suffering from IL-1 mediated autoinflammatory syndromes, indicating that the signature is not 
influenced by the activation status of IL-1, a cytokine that has powerful systemic effects.  
Here, the aggregate expression of the IL-36 signature genes (IL-36 score) was significantly increased 
in cases compared to controls (P=0.019) (Fig. 5.2.1). Of note, the analysis of a publicly available Ps 
dataset (whole-blood samples obtained from 33 cases vs 44 controls) [166] identified a moderate, but 
statistically significant, up-regulation of the same genes (P=0.001) (Fig. 5.2.1). This observation 






Fig. 5.2.1. The IL-36 score is significantly increased in psoriatic patients compared to controls. 
Dot plots showing a higher IL-36 score in whole blood of GPP (green, n=9) or Ps (blue, n=33) patients 
compared to controls (n=7 or n=44, respectively). The data for each group is presented as mean +/- 





5.3 Type-I-IFN related pathways are abnormally active in GPP 
5.3.1  Genes related to IFN signalling are enriched in the GPP transcriptome 
Differential expression analysis of the GPP RNA-seq data identified 117 Differentially Expressed Genes 
(DEGs), of which 111 were up-regulated (FC≥1.5 and FDR<0.05) (Fig. 5.3.1) (Appendix B). 
To better understand the biological significance of these findings, the list of up-regulated genes was 
used as input for Ingenuity Pathway Analysis (IPA). This revealed 12 enriched pathways (FDR <0.05) 
(Fig. 5.3.2), the most over-represented of which was IFN signalling (FDR = 4.7x10-6). 
Other enriched biological processes were also related to innate immunity. These included IL-6 






Fig. 5.3.1. Genes that are differentially expressed in the whole blood of GPP patients. 
Volcano plot showing differentially expressed genes. The genes meeting the significance threshold 
(horizontal dashed line, FDR <0.05) and the fold-change threshold (vertical dashed lines, FC>1.5; 
FC<0.7) are represented as black dots. The genes used to measure the IFN score (see 5.4) are labelled 







Fig. 5.3.2. Interferon signalling is the most significantly enriched pathway in GPP whole-blood. 
Bar plot illustrating the pathways that are enriched (FDR<0.05) among genes up-regulated in GPP 






5.3.2 Type-I IFN regulatory networks are active in the GPP whole-blood 
transcriptome 
To further dissect the role of IFN signalling in the context of GPP, an analysis of blood transcriptional 
modules (BTMs) was undertaken. BTMs are curated gene networks derived through the analysis of 
whole blood transcriptomic studies and through text-mining of the links between genes expressed in 
human blood [177]. Among these modules, only the ones that were active in the GPP RNAseq dataset 
were considered for further investigation. Their analysis identified nine BTMs that were enriched at 
an FDR <0.05, among the up-regulated genes in GPP (Fig. 5.3.3).  
Of note, all the over-represented modules are related to innate immunity, e.g.: dendritic cells and 
activated dendritic cells (FDR = 3.6x10-5 and 4.7x10-5, respectively). Moreover, a significant enrichment 
was observed for type I Interferon (FDR = 1.12x10-3), innate antiviral response (FDR = 1.13x10-3) and 
IRF2 target genes (FDR = 1.19x10-3), thus confirming the over-representation of IFN-related genes 







Fig. 5.3.3. Transcriptional modules related to innate responses are enriched among genes over-
expressed in GPP. 
Diagram showing transcriptional modules that are enriched (FDR <0.05) among genes up-
regulated in GPP whole-blood. The heatmap on the left reports the FDR associated with each 
module. The up-regulated genes mapping to the modules are indicated on the x axis and 





5.3.3 INF-α related transcription factors drive gene up-regulation in GPP 
As the previous analyses had demonstrated an enrichment of Type-I IFN related pathways, the list of 
up-regulated genes was further investigated in order to distinguish between the influence of IFN-α 
and -β signalling.  
As the IFN-α and –β pathways differ mainly in terms of upstream drivers [203], [204], the analysis 
focused on the transcription factors that bind the promoters of up-regulated genes. This identified 
114 enriched transcriptional regulators, with STAT3, STAT1 and IRF7 showing the most significant 
over-representation (FDR <10-13) (Fig. 5.3.4). Importantly, IRF7 is constitutively expressed in pDCs 
where it induces IFN-α expression [205]. Thus, the Type-I IFN signature observed in GPP patients is 






Fig. 5.3.4. Key Type-I IFN regulators driving gene up-regulation in GPP.  
Transcriptional networks showing the targets of STAT1, STAT3 and IRF7. All the genes included 





5.4 Overlap between the genes that are up-regulated in GPP and 
interferonopathies 
Abnormal type-I IFN levels are associated with a subset of monogenic autoinflammatory syndromes 
known as interferonopathies [206]. Interestingly, neutrophilia and systemic inflammation, which are 
typical manifestations of some of these syndromes (e.g. chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperature (CANDLE), Aicardi-Goutiéres syndrome (AGS)), are also key 
features of GPP.  
Here, an analysis of the genes that are over-expressed in CANDLE (8 cases vs 5 controls [167]), showed 
a significant overlap with those that are up-regulated in GPP (P <10-10) (Fig. 5.4.1). Interestingly, the 
same did not apply to the genes that are over-expressed in Cryopyrin Associated Periodic Syndrome 
(CAPS), an IL-1 mediated condition that was analysed as a negative control (P = 0.3) (Fig. 5.4.1). 







Fig. 5.4.1. Overlap between genes that are over-expressed in GPP and other autoinflammatory 
diseases. 
Venn diagrams showing: the overlap between the genes that are up-regulated in GPP (green) and in 
the Type-I-IFNpathy known as CANDLE (purple) (left), and the overlap between the genes that are up-
regulated in GPP and in the IL-1 driven autoinflammatory disease known as CAPS (orange) (right). P 






5.5 The IFN score is elevated in psoriatic cases compared to controls 
Given the strong type-I IFN signature observed in the GPP transcriptome, one could expect to observe 
an up-regulation of the genes encoding IFN-α itself. However the presence of numerous gene isoforms 
and their sequence homology hinder direct measurements of IFNA expression [207], [208]. Therefore 
Type-I IFN levels are typically measured through the analysis of target genes.  
Here, an IFN score (IS) was derived by measuring the aggregate expression of five (type-I) interferon 
inducible genes, as described by Rice et al [178]. In particular, the IFI6, IFIT3, IFITM3, OASL and PLSCR1 
genes were selected for analysis, based on their significant up-regulation in GPP whole-blood (Fig. 
5.3.1).  






Fig. 5.5.1. The IFN score is elevated in psoriatic patients compared to controls. 
Interferon Stimulated Genes show higher expression in the whole blood of GPP (green) and Ps (blue) 
patients compared to that of healthy controls. Each individual is presented as a dot. Data are shown 





For validation purposes, whole-blood samples were obtained from 35 additional GPP cases and 7 
healthy controls. The expression of the five signature genes was then measured by real-time PCR. The 
analysis of the expanded dataset (including the validation cohort as well as the samples that had been 
originally RNA-sequenced) showed a significantly higher score in cases compared to controls (P = 0.02) 
(Fig.5.5.2). 
Given, however, that the examined individuals came from a variety geographical regions, one could 
question whether this observation was affected by the ethnicity of the study participants. To address 
this issue, a clustering analysis was undertaken using individuals who had been RNA-sequenced by the 
10KImmunome project [165]. 
This showed that individuals of similar descent do not cluster together when the expression of the five 
signature genes is examined (Fig. 5.5.3). Moreover, data independently generated by Spielman et al. 
[209] shows that the expression of the five genes is comparable in European and Asian populations. 
Thus the IS is unlikely to be influenced by ethnicity and the difference between GPP cases and controls 
can be considered as genuine. 
Importantly, a moderate but statistically significant IS up-regulation was also observed in Ps whole 








Fig. 5.5.2. The analysis of an extended dataset validates the abnormal IS observed by RNA-seq. 
Dot plot showing an elevated IFN score in whole-blood samples of GPP patients (expanded dataset, 
n=44) compared to healthy controls (n=14). The data are presented as mean +/- standard deviation; 







Fig. 5.5.3. Expression of interferon signature genes across individuals of different descent. 
Heatmap of gene expression data of the five interferon signature genes (IFI6, IFIT3, IFITM3, OASL and 
PLSCR1) in 221 healthy individuals from the 10kImmunome project (44 Asians, 126 Europeans, 25 
Africans and African Americans, 26 Others). The dendogram at the top is showing that there is no 






5.6 IL-36 and IFN scores are highly correlated 
In order to investigate if there is a link between sustained IL-36 signalling and abnormal type-I IFN 
production, the correlation between IL-36 and IFN scores was measured in both GPP and Ps 
transcriptomes. The analysis showed a very strong correlation in GPP (rho = 0.93; P = 7.9x10-5) and a 
positive correlation in Ps (rho = 0.4; P = 5x10-3) (Fig 5.6.1). Although this result supports the hypothesis 






Fig. 5.6.1. IL-36 and IFN scores show significant positive correlation. 
Scatter plots showing that IL-36 and IFN scores are significantly correlated, in both GPP (top panel) 
and Ps (bottom panel) patients. Dashed regression lines are plotted with their 95% confidence 






The aim of this part of the project was to explore the role of IL-36 in the inflammatory responses driven 
by circulating leukocytes. 
Several studies described the genetic link between GPP and IL36RN mutations [79], [153], [161], [183], 
[210], [211]. Others have also investigated the role of IL-36 in immune mediated conditions such as 
psoriasis vulgaris and ulcerative colitis. Thus, the analysis of mouse models and human tissue has 
shown that IL-36 contributes to epithelial inflammation by promoting the polarization of Th17 cells 
and up-regulating the production of neutrophil and T cell chemoattractant.  
Conversely, the effects of IL-36 on circulating immune cells remain poorly understood. The work 
described in this chapter sought to address this issue through an investigation of GPP as a model of 
systemic inflammation caused by abnormal IL-36 signalling. 
Firstly, the analysis of whole-blood RNAseq identified an unexpected type-I IFN signature that could 
be experimentally validated in an extended patient dataset. Interestingly this is consistent with 
observations published by Wang et al. [19], who found that some loci related to type-I IFN production, 
such as IRF7, IFNAR1 and STAT1, are down-regulated in PBMCs of GPP patients treated with acitretin.  
Moreover, work carried by other members of the group demonstrated that a very significant type-I 
IFN signature can also be observed in neutrophils purified from the blood of affected individuals. In 
fact, RNA-sequencing of 8 GPP cases and 11 controls detected a marked over-representation of 
numerous transcriptional modules related to type-I IFN signalling, viral sensing and innate antiviral 
responses. These findings complement the results described here and suggest that the type-I IFN 
signature detected in whole blood is likely to be driven, at least in part, by gene up-regulation in 
neutrophils. 
However, given the manifestations of GPP (e.g. high fever, neutrophilia and high CRP levels) one could 




To address this possibility, it was important to demonstrate that: i) the GPP transcriptome is not 
similar to that of other inflammatory diseases presenting with systemic manifestations, and ii) type-I 
IFN signalling is driven by IL-36 activity in GPP. 
In this context, the analysis of publicly available data, showed that there is no meaningful overlap 
between the genes that are up-regulated in GPP and CAPS. While significant similarities were observed 
with CANDLE, the majority of over-expressed genes were not shared between the two conditions. 
These findings suggests that the type-I IFN signature observed in GPP is disease specific and therefore 
not secondary to its clinical manifestations. Nevertheless, it would be interesting to compare the GPP 
transcriptome with that of other conditions, such as Crohn’s disease and ulcerative colitis, to see if the 
disease specificity still applies. 
While the question relating to the causal role of IL-36 is only partially addressed in this chapter, 
computational analyses uncovered some interesting clues. First, there was a strong correlation 
between IL-36 and IFN scores, not only in the original GPP dataset, but also in patients with Ps.  
Second, the BTM analysis suggested an involvement of DCs and monocytes, which are the main 
producers of IL-36 in peripheral blood [69]. Finally, the identification of IRF7 as a transcription factor 
likely to drive gene up-regulation suggested that IL-36 might have an effect on IFN-α production by 
pDCs. 
In conclusion, the analyses presented in this chapter support the hypothesis that IL-36 contributes to 
systemic inflammation by up-regulating IFN-α production. However, interferons are produced upon 
viral infection or as a consequence of infection-like mechanisms [212] and not in response to other 
cytokines. Thus, various experimental approaches had to be used to reveal the relationship between 





6 The Role of IL-36 in systemic inflammation, 
experimental validation 
6.1 The IL-36 receptor is robustly expressed on the surface of plasmacytoid 
dendritic cells 
The analysis of GPP whole-blood presented in the previous chapter suggested that there might be a 
link between IL-36 signalling and type-I IFN production. To explore this hypothesis, it was first 
necessary to establish what immune cell types can respond to IL-36 stimulation. The expression of the 
IL-36 receptor (IL-36R) was therefore investigated by flow-cytometry.  
PBMCs and neutrophils obtained from healthy individuals and GPP patients were stained with a 
cocktail of antibodies, targeting IL-36R, as well as cell-specific surface markers. 
Interestingly, no receptor expression was observed on T cells, even after activation with CD3/CD28 
beads (Fig. 6.1.1). While Arakawa et al. have described a response of T helper cells to IL-36 treatment, 
our findings are in keeping with those of Fosters et al, who also showed no expression of IL-36R on T 
cells [61], [120]. 
Among adaptive immune cells, the strongest IL-36R expression was therefore observed in B cells (Fig. 
6.1.1). This was surprising because there is no evidence of B cells being linked to plaque or pustular 
psoriasis.  
Conversely, the highest proportion of innate immune cells expressing IL-36R, was found among pDCs 
and mDCs, with no IL-36R expression detected on the surface of isolated neutrophils (Fig. 6.1.2). While 
no significant difference was observed between GPP cases and healthy controls (Fig. 6.1.3), IL-36R 






Fig. 6.1.1. IL-36R expression in adaptive immune cells. 
(A-C) Representative flow cytometry plots are shown, alongside fluorescence minus one (FMO, blue 
gates) controls for each population. The following cell types were analysed: (A) T cells (gated as CD3+, 
CD19-, CD14- and CD16-); (B) purified T cells cultured for 6 days in the presence of CD3/C28 and gated 






Fig. 6.1. 2. IL-36R expression in innate immune cells.  
(A-D) Representative flow cytometry plots of IL-36R surface expression in innate immune cells. 
Fluorescence minus one (FMO, blue gates) controls are shown for each population. The following cell 
types were analysed: (A) purified neutrophils (gated as CD14-, CD15+, CD16+ cells); (B) innate 
lymphoid cells (lineage- (CD3-, CD4-, CD19-, CD20-, CD56-), CD127+); (C) monocytes (CD3-, CD20-, 
CD19-, CD56-) separated into classical (CD16-, CD14high), intermediate (CD16+, CD14+) and pro-
inflammatory (CD16high, CD14-) populations; (D) pDCs (lineage-, HLADR+, CD123+, CD11c-) and mDCs 







Fig. 6.1.3. IL-36R expression summary data.  
Bar plots showing the percentage IL-36R+ cells in each leukocyte population (n= 3 GPP cases and n = 3 
healthy donors (HD) for PBMCS; n=4 GPP cases and 4 healthy donors for neutrophils). (A) Bar plot for 
B cells and T cells gated as in Fig. 6.1.1. (B) Bar plots for purified CD4+ and CD8+ T cells after 6 days of 
in vitro activation. (C) Bar plots for innate immune cells gated as in Fig. 6.1.2. Data are presented as 





6.2 IL-36 potentiates IFN-α production 
Given that IL-36R is expressed on the surface of pDCs, we hypothesised that IL-36 cytokines potentiate 
type-I IFN production in these cells. To investigate this possibility, PBMCs obtained from healthy 
donors were pre-treated with IL-36α, or medium, and then stimulated with CpG-containing DNA 
(hence CpG), a Toll-like receptor (TLR)-9 ligand which induces IFN-α release by pDCs.  
After 6h treatment with CpG, the mRNA expression of the interferon signature genes was markedly 
increased (Fig. 6.2.1). Interestingly, this up-regulation was more pronounced in cells that had been 
pre-stimulated with IL-36 (P<0.05 for IFIT3, OASL and PLSCR1). These findings were also confirmed at 
the protein level, as an increase in IFN-α release was observed in the supernatants of cultures pre-
treated with IL-36 (Fig. 6.2.1). 
To further explore these results, flow cytometry experiments were undertaken in order to identify the 
cell-type(s) driving IFN-α production. The assays focused on B cells and pDCs, since these showed the 
highest IL-36R expression. 
While IFN-α was not detected in B cells under any conditions, it was present in pDCs stimulated with 
CpG. Importantly, the proportion of IFNα+ cells was higher among pDCs that had been pre-treated 







Fig. 6.2. 1. IL-36 pre-treatment enhances IFN-α responses in PBMCs. 
(A) PBMCs were stimulated with CpG for 6h, in the presence or absence of IL-36 pre-treatment (6h). 
The expression of the five interferon signature genes was then measured by real-time PCR and 
normalised to that of the B2M gene. Data represent the mean +/- SEM of results obtained in three 
independent donors, each stimulated in triplicate (B) Following PBMC stimulation, IFN-α production 
was measured by ELISA. Each line in the plot represents an independent healthy donor. Data are 







Fig. 6.2. 2. IL-36 potentiates IFN-α production in pDCs but not B cells. 
Following PBMCs stimulation, the percentage of IFN-α+ B cells (top panel) and pDCs (bottom panel) 
was determined by flow cytometry. Representative sets of zebra plots are shown for both populations, 
while the panel on the bottom right summarizes the data obtained for pDCs (n=3 healthy donors). 





6.3 IL-36 up-regulates PLSCR1 expression in pDCs 
The above observation suggests that the effect of IL-36 on IFN-α production is mediated by pDCs. 
Although this is a reasonable conclusion, it does not explain the underlying mechanisms.  
Interestingly, an analysis of the results obtained in previous experiments revealed that IL-36 can 
increase PLSCR1 expression even in the absence of CpG. This result, which was confirmed through the 
analysis of further donors (Fig. 6.3.1) is noteworthy, since PLSCR1 encodes a phospholipid scramblase 
that is responsible for the endosomal translocation of TLR-9. Thus, the up-regulation of PLSCR1 could 
account for the enhanced TLR-9 activation observed in PBMCs treated with IL-36. 
To further explore this possibility, pDCs were isolated from the blood of healthy donors and stimulated 
with CpG, with or without IL-36 pre-treatment. PLSCR1 expression was then measured by flow 
cytometry.  
As expected, these experiments identified a homogenous pDC population expressing PLSCR1. 
Importantly, a significant increase in PLSCR1 mean fluorescence intensity (MFI) was observed in IL-36 
treated cells compared to untreated (Fig. 6.3.1). This demonstrates that IL-36 acts directly on 






Fig. 6.3.1. IL-36 up-regulates the expression of PLSCR1. 
(A) Real time qPCR showing up-regulation of PLSCR1 upon IL-36 stimulation. The bar plot summarises 
the data obtained in five healthy donors. (B) From the left, flow-cytometry gate showing that virtually 
all pDCs express PLSCR1 following IL-36 treatment. PLSCR1 mean fluorescence intensity (MFI) was 
measured by flow cytometry. The panel on the left shows a representative histogram (control in 
orange and treated in blue), while the plot on the right summarises the results obtained in the three 






The aim of this chapter was to dissect the molecular mechanisms linking IL-36 signalling to abnormal 
type-I IFN production. The first step was to identify the cell types that respond to IL-36 stimulation.  
No IL-36R expression was observed on T cells, which is in keeping with the results reported by Foster 
et al [61]. Conversely, Arakawa et al. showed that CD4+ T cells undergo clonal expansion in response 
to IL-36. This facilitates Th17 polarization and activation, in blood as well as skin.  
It is worth noting, however, that the effect observed by Arakawa et al could be an indirect one, as the 
authors did not show IL-36R expression in circulating T-cells [213]. In fact, the only direct evidence for 
IL-36R expression in T lymphocytes was shown in the leukocytes infiltrating GPP lesions. This suggests 
that different tissue-dependent stimuli might induce trafficking of IL-36R on the surface of T cells and 
that these signals might be mainly active in the skin (rather than the blood) of GPP patients. 
Similar considerations may apply to neutrophils. These cells are key mediators of inflammation in GPP, 
as they infiltrate skin pustules and produce pro-inflammatory cytokines [183], [214]. Nevertheless, 
circulating neutrophils do not express IL-36R and other members of the group have shown that they 
do not respond to IL-36 stimulation. Of note, Wang et al have reported that IL-36R is expressed in the 
neutrophils that infiltrate the polyps of chronic rhinosinusitis patients [53]. Thus, the existence of 
tissue-specific factors influencing IL-36R expression has also been demonstrated for neutrophils. 
The highest percentage of IL-36R+ cells was observed among B lymphocytes. This is in agreement with 
the data reported by Chu et al., who detected IL-36R expression on regulatory and CD19+B cells [215].  
Of note, a role of B cells in innate immunity has been emerging in recent years. Tonti E. et al, for 
example showed that B cells can be activated by NK cells in a T-cell-independent fashion [216]. An 
innate-like function has also been described for marginal zone B cells, as these can mount rapid 




obtained by the Capon group suggest that IL-36R is strongly expressed in circulating marginal zone B-
cells, it will be interesting to further investigate the role of this subset in autoinflammation.  
Here, follow-up experiments were focused on pDCs, as a substantial proportion of these cells, which 
are major IFN-α producers, expressed IL-36R. 
Real-time and flow cytometry experiments demonstrated that IL-36 up-regulates PLSCR1 in pDCs. 
Given that IL-36 can signal through mitogen-activated protein kinases (MAPK) [218], the latter 
pathway is likely to contribute PLSCR1 up-regulation, through a cross-talk with STAT1 signalling. In 
fact, other members of our group have shown that treatment of PBMCs with a MAPK inhibitor 
abolishes the effects of IL-36 on PLSCR1 mRNA levels.  
Interestingly, Talukder et al. reported that primary pDCs from Plscr1-deficient mice produced less IFN-
α in response to CpG than pDCs from wild-type mice [219]. This was due to the fact that Plscr1 KO 
mice were not able to recruit TLR-9 to the endosome of pDCs. As a consequence, there was no 
downstream signalling leading to the transcriptional activation of IFNA genes.  
Our experiments show that IL-36 may have an opposite effect, up-regulating PLSCR1 expression and 
therefore potentiating TLR-9 activation and IFN-α production. 
In conclusion, the findings described in this chapter identify a new IL-36/IFN-α axis that is active in the 
pDCs of psoriatic patients. More specifically, the data suggests that IL-36 cytokines produced by mDCs 
have a priming effect on pDCs. Thus, when the latter are exposed to a viral infection or viral-like trigger 
(e.g. nucleic acids released by apoptotic cells), they produce excessive amounts of IFN-α. Importantly, 
type-IFN can in turn up-regulate PLSCR1 expression, driving a pro-inflammatory feedback loop in pDCs 
(Fig. 6.5.1).  
Given that IL-36 signalling is abnormally active in the blood of Ps and GPP patients, IL-36 driven IFN-α 
up-regulation is likely to contribute to the pathogenesis of both conditions. While additional studies 




worth pointing out that IFN-α and -β have been repeatedly implicated in the pathogenesis of co-
morbidities such as psoriatic arthritis and atherosclerosis [74], [220]. So, the immune axis described 







Fig. 6.4.1. IL-36/IFN-α axis: proposed model. 
IL-36 produced by mDCs up-regulates PLSCR1 expression in pDCs, enhancing IFN-α release via TLR-9. 
IFN-α, in turn, induces further PLSCR1 transcription, thus promoting a positive feedback loop. 






While numerous studies have documented an up-regulation of IL-36 in psoriatic skin [61], [221, p. 36], 
the mechanisms whereby this cytokine contributes to disease pathogenesis have mostly been 
investigated in mouse models [157], [198]. The latter, however, do not recapitulate some of the key 
features of psoriasis (e.g. the chronic nature of the condition). Thus, the aim of this study was to 
generate new insights into the pathogenic role of IL-36, by applying transcriptomic approaches to the 
analysis of human tissues.  
7.1 Transcriptomic to unravel mechanisms of inflammatory diseases 
RNA-seq is an advantageous tool for the study of gene expression patterns in different organisms and 
tissues. A key feature in the design of these experiments is the selection of a cell type that is relevant 
to the disease of interest. In the context of plaque psoriasis, for example, keratinocytes are often used 
as a model [187], [222]. Since they are the most abundant cell-type in the epidermis and show robust 
IL-36R expression, keratinocytes have also been examined in this thesis, with the purpose of 
investigating the consequences of IL-36 up-regulation in psoriatic skin.  
While the analysis of a single cell type allowed the definition of a very specific IL-36 signature, it is 
important to bear in mind that skin is a heterogeneous tissue, characterised by the cross-talk between 
keratinocytes, fibroblasts and resident immune cells [223]. To better understand the role of IL-36 in 
this complex environment, future studies should investigate the effects of the cytokine on cultured 
skin biopsies or infiltrating leukocytes isolated from patient lesions. 
In the second part of the study, the systemic effects of IL-36 were examined through the analysis of 
circulating immune cells. While its ease of access makes blood an attractive choice for transcription 
profiling experiments, the need to eliminate globin transcripts can affect RNA quality (in our hands, 




with the lowest median gene expression [224]. This affects signal to noise ratios and often reduces 
statistical power, as demonstrated by the relatively small number of DEGs detected in chapter 4 (< 
200). 
Despite the limitations inherent to the choice of particular tissues, transcription profiling can offer 
important insights into disease mechanisms. This is especially the case when the identification of DEG 
is followed by the study of transcriptional networks or enriched pathways. Of note, the algorithms 
that are applied in these follow-up analyses rely on the availability of functional annotation for the 
genes of interest. While several databases have collated information on human genes (e.g. Gene 
Ontology [104], DAVID [225],Molecular Signature Database (MSigDB) [226] and IPA (Qiagen)), up to 
50% of human transcripts cannot be annotated with functional terms. This knowledge gap can 
sometimes be filled with a guilt-by-association approach, whereby gene function is inferred based on 
the annotation of co-expressed genes (e.g. GeneMania) [227], [228]. However, the depth of these 
predicted annotations is variable. 
Transcriptomic studies can also offer pathogenic insights by facilitating the identification of non-
coding disease alleles. For instance, Cummings et al recently integrated whole-genome sequencing 
and RNA-seq to identify splice-altering mutations in deep intronic regions [229]. Likewise, Kremer et 
al demonstrated the advantage of transcriptome sequencing in the molecular diagnosis of 
mitochondrial disease [230]. Given that the GPP genes described so far (IL36RN, CARD14 and AP1S3) 
only account for a minority of disease cases (~25%), the whole-blood expression profiles generated in 
this study could be queried with tools that allow the identification of abnormal transcripts isoforms 
(e.g. de novo transcript assembly ). These could then be linked to non-coding sequence changes that 
are predicted to affect splicing enhancers and silencers.  
Finally, the development of single-cell RNAseq (scRNA-seq) has further expanded the scope of 
transcriptomic studies and their potential to illuminate disease pathways [231]. Regulatory networks 




impossible, as exemplified by the recent discovery of the first quantitative trait loci for co-expression 
[232]. In this context, the Capon lab has recently undertaken the scRNAseq of PBMCs stimulated with 
IL-36. These experiments have the potential to further dissect the pro-inflammatory networks that are 
activated by this cytokine and up-regulated in psoriatic patients. 
 
7.2 The pathogenic role of IL-36 
The work presented in this thesis (chapter 4) demonstrates that IL-36 is a key driver of psoriatic 
inflammation, as it amplifies the effects of IL-17 signalling in skin. This has now been confirmed in a 
number of independent studies. For example, German et al have shown that calcipotriol (a vitamin D3 
analogue commonly used for the treatment of psoriasis) relieves skin inflammation by down-
regulating IL-36 levels and consequently reducing IL-17 activation [233]. Mercurio et al have also 
reported that an imbalance between IL-36 and IL-38 (an immunoregulatory cytokine that is a 
paralogue of IL-36Ra) is associated with increased psoriasis severity [234].  
Of note, additional associations between IL-36 and pustular skin phenotypes have also been 
described. For example, it has been shown that the culprit drugs causing Acute Generalised 
Exanthematous Pustulosis (a severe drug reaction mimicking the presentation of GPP) trigger the 
production of IL-36 in cultured patient keratinocytes [21]. 
Thus, the role of IL-36 in skin inflammation has now been investigated in a variety of diseases and 
experimental systems. Conversely its systemic effects have received little attention. 
Here, the analysis of whole-blood gene expression in GPP cases vs. healthy individuals has led to the 
discovery of a new IL-36/type-I IFN axis. Of note, IL-36 scores were elevated in all patients, even 
though IL36RN mutations were only found in a minority. This supports the notion that genetic defects 




Follow-up mechanistic studies showed that IL-36R expression was highest among pDCs and B cells. 
The effects of IL-36 on pDCs was further explored and linked to the up-regulation of PLSCR1 and 
activation of TLR-9 signalling.  
While the role of IL-36 in B cell biology was not investigated in this study, another member of the 
Capon group has since examined the expression of IL-36R in B cell sub-populations. These experiments 
have shown that IL-36R levels are highest in naïve mature and Marginal Zone B cells. The latter are 
innate-like B lymphocytes, which rapidly acquire immune regulatory activities through the secretion 
of natural IgM and IL-10 [236]. They might therefore have a role in breaking self-tolerance and, 
potentially, in the development of immune related disorders.  
Importantly, abnormal IL-36 activity has now been detected in other inflammatory diseases beyond 
psoriasis. In fact, studies of animal models have repeatedly implicated IL-36 in the pathogenesis 
ulcerative colitis, whereas measurement of serum cytokine levels have suggested a link with systemic 
lupus erythematosus [84], [215]. Given the role of pDCs and B cells in the above conditions, future 
studies should seek to determine whether IL-36 mediated activation of these cell types contributes to 





7.3 IL-36 as a therapeutic target in psoriasis 
IL-36 signalling inhibition is emerging as a safe alternative to available treatments for Ps and GPP. For 
instance, Mahil et al showed that individuals born without a functioning IL-36R (human IL1RL2 
knockouts) are healthy and do not show an increased susceptibility to infections [20]. These 
observations suggested that IL-36 blockade is unlikely to have major adverse consequence on human 
immune function. This notion was subsequently confirmed in clinical trials of IL-36R blockers. 
AnaptysBio recently carried out a placebo-controlled, Phase 1 trial of ANB019, a neutralising, anti-
IL36R antibody (ClinicalTrials.gov Identifier: NCT03619902). This showed that IL-36R blockade is well 
tolerated. Only minor side effects were observed, with mild infections of the upper respiratory tract 
seen in 28% of subjects receiving the drug.  
Following these encouraging results, a Phase 2 clinical trial of ANB019 has been initiated in 
Generalized Pustular Psoriasis (NCT03633396) [25]. Of note, the study is being led from St John’s 
Institute of Dermatology, where skin and blood samples are actively being collected before and after 
treatment. Plans are in place for the transcription profiling of these samples, which is expected to yield 
further insights into the pathogenic role of IL-36 and the immunological effects of its blockade. 
A parallel phase I trial of a second IL-36R inhibitor (BI 655130) has recently been completed by 
Boheringer Ingelheim (NCT03482635). The study included a small number of GPP patients (n=7), 
where complete, or near complete clearance of skin lesions was observed, regardless of IL36RN 
mutation status [25]. The same agent is now being tested in ulcerative colitis and palmar plantar 
pustulosis.  
While the studies described above included a small number of participants, they seem to consistently 
show that IL-36 blockers are safe and beneficial. In this context, further studies of the immune 
pathways and diseases that are affected by IL-36 de-regulation have the potential to identify other 
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Appendix A: Enriched Pathways in KCs stimulated with IL-36 
Ingenuity Canonical Pathway FDR_IL-
36α 





Acute Phase Response Signaling 3.07E-06 1.52E-05 1.87E-07 YES 
Agranulocyte Adhesion and Diapedesis 1.76E-07 6.93E-07 1.17E-07 YES 
Airway Pathology in Chronic Obstructive Pulmonary Disease 4.21E-04 2.11E-03 5.12E-04 YES 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 3.01E-05 1.00E-03 5.12E-05 YES 
Antioxidant Action of Vitamin C 3.06E-03 2.35E-03 8.32E-04 YES 
Atherosclerosis Signaling 1.70E-10 2.46E-10 5.76E-11 YES 
Bladder Cancer Signaling 8.52E-03 NA 1.09E-02 NO 
CCR3 Signaling in Eosinophils NA 2.53E-02 4.81E-02 NO 
Communication between Innate and Adaptive Immune Cells 1.63E-03 1.66E-02 3.93E-04 YES 
Complement System 2.41E-02 2.60E-03 3.54E-03 YES 
Dendritic Cell Maturation 7.86E-04 6.81E-03 3.39E-04 YES 
Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F 3.03E-05 4.00E-04 4.58E-05 YES 
Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-
17F 
4.78E-02 NA NA NO 
Eicosanoid Signaling 3.01E-03 2.18E-04 6.23E-04 YES 
Estrogen Biosynthesis 2.71E-02 NA 3.14E-02 NO 
Fatty Acid Î±-oxidation NA 2.53E-02 NA NO 
Fc Epsilon RI Signaling NA 1.66E-02 8.35E-03 NO 
FXR/RXR Activation 1.63E-03 6.70E-03 8.71E-05 YES 
Glycogen Degradation III 2.80E-02 NA 3.14E-02 NO 
Graft-versus-Host Disease Signaling 6.80E-03 3.44E-02 8.33E-03 YES 
Granulocyte Adhesion and Diapedesis 1.50E-08 4.74E-08 6.09E-10 YES 




Hepatic Cholestasis 8.93E-06 2.35E-03 1.98E-05 YES 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.61E-05 5.42E-04 2.55E-04 YES 
HMGB1 Signaling 3.82E-02 NA NA NO 
IL-10 Signaling 4.24E-04 5.81E-03 6.61E-04 YES 
IL-17A Signaling in Airway Cells 9.77E-05 4.44E-04 2.41E-05 YES 
IL-17A Signaling in Fibroblasts 1.87E-04 2.93E-04 2.41E-05 YES 
IL-17A Signaling in Gastric Cells 9.33E-03 3.44E-02 8.86E-04 YES 
IL-17 Signaling 3.80E-02 NA 1.88E-03 NO 
IL-1 Signaling 9.98E-03 NA 1.26E-02 NO 
IL-6 Signaling 4.59E-05 2.11E-03 8.94E-05 YES 
IL-8 Signaling 1.51E-02 8.33E-03 6.74E-03 YES 
Inflammasome pathway 2.38E-05 2.93E-04 3.07E-05 YES 
iNOS Signaling 5.06E-03 5.10E-03 6.43E-03 YES 
Leukocyte Extravasation Signaling NA 1.23E-02 NA NO 
LPS/IL-1 Mediated Inhibition of RXR Function NA 6.59E-03 3.71E-02 NO 
LXR/RXR Activation 6.35E-06 9.15E-05 1.74E-06 YES 
Lymphotoxin Î² Receptor Signaling 1.90E-02 NA 2.24E-02 NO 
MIF-mediated Glucocorticoid Regulation 1.24E-05 1.92E-06 1.34E-06 YES 
MIF Regulation of Innate Immunity 3.14E-05 8.46E-06 5.02E-06 YES 
NF-ÎºB Signaling 2.38E-05 1.74E-03 4.58E-05 YES 
p38 MAPK Signaling 5.75E-06 1.09E-05 1.34E-06 YES 
Phospholipase C Signaling NA 9.77E-03 1.67E-02 NO 
Phospholipases 1.51E-02 3.85E-03 2.94E-03 YES 
PPAR Signaling 1.98E-03 2.00E-02 2.82E-03 YES 
RAR Activation 1.32E-02 NA 5.60E-03 NO 
Retinoate Biosynthesis I 2.06E-03 1.20E-02 2.70E-03 YES 
Retinol Biosynthesis 2.80E-02 NA NA NO 
Role of Cytokines in Mediating Communication between Immune Cells 1.06E-07 7.32E-06 2.07E-07 YES 




Role of IL-17A in Arthritis 6.35E-06 2.18E-04 1.02E-05 YES 
Role of IL-17A in Psoriasis 8.56E-14 9.83E-12 2.30E-13 YES 
Role of IL-17F in Allergic Inflammatory Airway Diseases 4.50E-05 8.54E-04 7.63E-06 YES 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 1.02E-04 1.70E-03 2.02E-05 YES 
Role of MAPK Signaling in the Pathogenesis of Influenza 2.35E-02 6.81E-03 8.32E-04 YES 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 3.08E-02 NA 1.52E-02 NO 
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 2.46E-03 3.16E-03 8.32E-04 YES 
Role of Tissue Factor in Cancer NA NA 9.21E-03 NO 
Sperm Motility NA 6.59E-03 2.41E-03 NO 
Synaptic Long Term Depression NA 4.27E-02 1.98E-02 NO 
TNFR1 Signaling 7.10E-03 3.62E-02 8.57E-03 YES 
TNFR2 Signaling 1.26E-03 7.11E-03 1.57E-03 YES 
Toll-like Receptor Signaling 1.06E-07 8.70E-06 2.07E-07 YES 
TREM1 Signaling 8.52E-05 4.00E-04 1.46E-04 YES 
TWEAK Signaling 2.00E-02 NA 2.23E-02 NO 
VDR/RXR Activation NA NA 7.57E-03 NO 
VEGF Family Ligand-Receptor Interactions 4.04E-02 1.66E-02 1.12E-02 YES 
Xenobiotic Metabolism Signaling NA 3.34E-02 NA NO 




Appendix B: Genes significantly up-regulated in GPP whole blood 
Symbol log2FoldChange P value FDR 
CD177 3.04E+00 5.28E-06 8.40E-03 
MMP9 2.40E+00 2.67E-04 3.11E-02 
IFITM3 1.96E+00 1.72E-04 2.68E-02 
FCGR1A 1.95E+00 3.25E-04 3.39E-02 
TNFAIP6 1.84E+00 5.08E-06 8.40E-03 
LINC01506 1.67E+00 5.51E-05 2.22E-02 
FCGR1B 1.65E+00 7.17E-05 2.42E-02 
IL1R2 1.63E+00 1.12E-04 2.42E-02 
RAB20 1.59E+00 8.79E-05 2.42E-02 
LINC00694 1.58E+00 2.23E-04 2.81E-02 
SERPING1 1.56E+00 4.11E-08 3.26E-04 
BTNL8 1.53E+00 5.12E-06 8.40E-03 
VNN2 1.47E+00 1.85E-04 2.68E-02 
PLSCR1 1.45E+00 1.29E-05 1.02E-02 
LY96 1.44E+00 1.67E-04 2.68E-02 
GRINA 1.40E+00 1.79E-04 2.68E-02 
CEBPD 1.39E+00 2.06E-05 1.17E-02 
DSC2 1.36E+00 5.06E-04 4.23E-02 
FCAR 1.35E+00 4.05E-04 3.67E-02 
NAMPT 1.34E+00 2.88E-04 3.14E-02 
DUSP1 1.32E+00 1.54E-05 1.02E-02 
TREM1 1.31E+00 9.28E-05 2.42E-02 
FUT7 1.31E+00 4.07E-04 3.67E-02 
KREMEN1 1.29E+00 1.53E-05 1.02E-02 
PLAUR 1.29E+00 1.14E-04 2.42E-02 
SCO2 1.28E+00 8.80E-06 9.99E-03 
SAT1 1.28E+00 8.23E-05 2.42E-02 
IFI6 1.27E+00 5.57E-04 4.45E-02 
OASL 1.26E+00 1.16E-05 1.02E-02 
SECTM1 1.25E+00 1.67E-04 2.68E-02 
SH2B2 1.25E+00 1.22E-04 2.42E-02 
IL1R1 1.24E+00 6.62E-04 4.79E-02 
MIR223 1.23E+00 1.08E-04 2.42E-02 
BCL3 1.21E+00 3.97E-04 3.67E-02 
CEBPB 1.21E+00 1.19E-04 2.42E-02 
TGFA 1.21E+00 5.02E-05 2.22E-02 
BRI3 1.21E+00 2.48E-04 2.98E-02 
NINJ1 1.21E+00 1.73E-04 2.68E-02 
IFIT3 1.20E+00 3.53E-04 3.47E-02 
TXN 1.19E+00 1.13E-04 2.42E-02 
NFIL3 1.18E+00 6.06E-04 4.50E-02 




CCDC71L 1.16E+00 4.82E-04 4.07E-02 
PILRA 1.15E+00 8.89E-05 2.42E-02 
TMEM120A 1.15E+00 9.97E-05 2.42E-02 
LST1 1.15E+00 2.22E-04 2.81E-02 
CD14 1.14E+00 2.70E-04 3.11E-02 
CSRNP1 1.14E+00 1.96E-04 2.68E-02 
SCARF1 1.12E+00 5.65E-04 4.45E-02 
KLHDC8B 1.11E+00 1.89E-04 2.68E-02 
CYP27A1 1.11E+00 7.73E-06 9.99E-03 
SMARCD3 1.10E+00 4.64E-04 4.01E-02 
NCF1 1.09E+00 3.21E-04 3.39E-02 
ASPRV1 1.09E+00 2.83E-04 3.12E-02 
CFP 1.08E+00 9.23E-05 2.42E-02 
ZNF467 1.08E+00 2.80E-04 3.12E-02 
STX11 1.08E+00 3.23E-05 1.60E-02 
TMEM140 1.07E+00 1.17E-04 2.42E-02 
TSC22D3 1.07E+00 2.54E-05 1.34E-02 
VNN3 1.06E+00 6.72E-04 4.81E-02 
CCR1 1.05E+00 3.46E-04 3.44E-02 
SLC16A3 1.04E+00 4.13E-04 3.69E-02 
CEP19 1.04E+00 1.66E-04 2.68E-02 
GLIPR2 1.04E+00 6.03E-04 4.50E-02 
DDX60L 9.71E-01 1.68E-04 2.68E-02 
LAT2 9.70E-01 4.35E-04 3.83E-02 
F2RL1 9.60E-01 9.49E-05 2.42E-02 
MXD1 9.49E-01 6.31E-04 4.60E-02 
HIP1 9.41E-01 8.77E-05 2.42E-02 
WAS 9.39E-01 6.02E-04 4.50E-02 
B4GALT5 9.39E-01 4.74E-04 4.05E-02 
IL10RB 9.30E-01 6.84E-04 4.85E-02 
NFAM1 9.30E-01 5.18E-04 4.25E-02 
PARP9 9.22E-01 1.52E-05 1.02E-02 
TMEM164 9.16E-01 2.77E-04 3.12E-02 
IFIT2 9.12E-01 3.28E-04 3.39E-02 
FAM214B 9.00E-01 5.94E-04 4.50E-02 
RNF130 8.99E-01 2.69E-04 3.11E-02 
CTSL 8.96E-01 2.01E-04 2.71E-02 
HSD17B11 8.96E-01 1.80E-04 2.68E-02 
SRA1 8.91E-01 5.78E-04 4.49E-02 
SHISA5 8.90E-01 6.52E-05 2.42E-02 
IL13RA1 8.71E-01 3.39E-04 3.41E-02 
CTSB 8.64E-01 3.74E-04 3.58E-02 
CHMP5 8.63E-01 8.97E-05 2.42E-02 




STAB1 8.55E-01 2.29E-04 2.85E-02 
IRF1 8.46E-01 1.87E-05 1.14E-02 
RHBDD2 8.34E-01 1.87E-04 2.68E-02 
ODF3B 8.26E-01 6.91E-04 4.86E-02 
ERGIC1 8.19E-01 5.43E-04 4.41E-02 
DGAT1 7.87E-01 1.58E-04 2.68E-02 
MX2 7.86E-01 3.39E-04 3.41E-02 
SOCS3 7.79E-01 3.79E-04 3.58E-02 
SOWAHD 7.76E-01 2.05E-04 2.71E-02 
EEPD1 7.69E-01 1.95E-04 2.68E-02 
NMI 7.47E-01 4.38E-04 3.83E-02 
NOD2 7.44E-01 5.12E-05 2.22E-02 
NEU1 7.44E-01 7.10E-04 4.91E-02 
MYADM 7.33E-01 2.42E-04 2.95E-02 
TAP1 7.29E-01 1.86E-04 2.68E-02 
GBP5 7.07E-01 5.82E-04 4.49E-02 
GALNT3 6.83E-01 5.19E-04 4.25E-02 
PSMB8 6.75E-01 1.39E-04 2.63E-02 
APOL2 6.68E-01 2.95E-04 3.17E-02 
APOL1 6.67E-01 5.60E-05 2.22E-02 
STK19 6.46E-01 1.14E-04 2.42E-02 
CMTM7 6.39E-01 1.27E-04 2.46E-02 
H2AFY 6.07E-01 7.34E-04 4.98E-02 
SEC61B 5.67E-01 7.46E-04 4.98E-02 
SF3B5 4.07E-01 2.15E-04 2.80E-02 
TMPO -4.27E-01 5.59E-04 4.45E-02 
CARNS1 -6.35E-01 3.59E-04 3.48E-02 
ZNF37BP -6.65E-01 7.02E-04 4.90E-02 
PLEKHA1 -7.41E-01 7.41E-04 4.98E-02 
CLUHP3 -9.01E-01 6.13E-04 4.51E-02 
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